

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in treating Parkinson&rsquo;s... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-260/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-260" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in treating Parkinson’s disease" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in treating Parkinson&rsquo;s disease.">
            <meta name="og:description" content="Read the latest article version by Wolfgang H. Oertel, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10881">
            <meta name="article-id" content="10100">
            <meta name="dc.title" content="Recent advances in treating Parkinson&rsquo;s disease">
            <meta name="dc.description" content="This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson&rsquo;s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) &mdash;a methodological challenge to be met in the future.">
            <meta name="dc.subject" content="Parkinson's disease, prodromal stage, motor symptoms, non-motor symptoms, disease modifying treatment">
            <meta name="dc.creator" content="Oertel, Wolfgang H.">
            <meta name="dc.date" content="2017/03/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10100.1">
            <meta name="dc.source" content="F1000Research 2017 6:260">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Parkinson's disease">
            <meta name="prism.keyword" content="prodromal stage">
            <meta name="prism.keyword" content="motor symptoms">
            <meta name="prism.keyword" content="non-motor symptoms">
            <meta name="prism.keyword" content="disease modifying treatment">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/03/13">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="260">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10100.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-260">
            <meta name="citation_title" content="Recent advances in treating Parkinson&rsquo;s disease">
            <meta name="citation_abstract" content="This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson&rsquo;s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) &mdash;a methodological challenge to be met in the future.">
            <meta name="citation_description" content="This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson&rsquo;s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) &mdash;a methodological challenge to be met in the future.">
            <meta name="citation_keywords" content="Parkinson's disease, prodromal stage, motor symptoms, non-motor symptoms, disease modifying treatment">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Wolfgang H. Oertel">
            <meta name="citation_author_institution" content="Department of Neurology, University Clinic, Philipps Universit&auml;t Marburg, Marburg, Germany">
            <meta name="citation_author_institution" content="Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany">
            <meta name="citation_publication_date" content="2017/03/13">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="260">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10100.1">
            <meta name="citation_firstpage" content="260">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-260/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-260.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10881 /> <input type=hidden id=articleId name=articleId value=10100 /> <input type=hidden id=xmlUrl value="/articles/6-260/v1/xml"/> <input type=hidden id=xmlFileName value="-6-260-v1.xml"> <input type=hidden id=article_uuid value=a8342594-31c1-4c9c-8d79-c7dfb96046c4 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in treating Parkinson’s disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10100.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10100.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-260"
  },
  "headline": "Recent advances in treating Parkinson’s disease",
  "datePublished": "2017-03-13T16:13:13",
  "dateModified": "2017-03-13T16:13:13",
  "author": [
    {
      "@type": "Person",
      "name": "Wolfgang H. Oertel"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson&rsquo;s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) &mdash;a methodological challenge to be met in the future."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-260",
            "name": "Recent advances in treating Parkinson’s disease"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in treating Parkinson’s disease </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10881 data-id=10100 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10100.1" data-recommended="" data-doi="10.12688/f1000research.10100.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-260/v1/pdf?article_uuid=a8342594-31c1-4c9c-8d79-c7dfb96046c4" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10100-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10100-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10100-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Oertel WH. Recent advances in treating Parkinson’s disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):260 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10100.1" target=_blank>https://doi.org/10.12688/f1000research.10100.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10100-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10100 id=track-article-signin-10100 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10100?target=/articles/6-260">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10881 /> <input name=articleId type=hidden value=10100 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in treating Parkinson’s disease</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:oertelw@med.uni-marburg.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Wolfgang H. Oertel</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:oertelw@med.uni-marburg.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Wolfgang H. Oertel</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 Mar 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10100.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Neurology, University Clinic, Philipps Universit&auml;t Marburg, Marburg, Germany<br/> <sup>2</sup> Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=7988-20549></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=20852-20550></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Parkinson's disease, prodromal stage, motor symptoms, non-motor symptoms, disease modifying treatment </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Wolfgang H. Oertel (<a href="mailto:oertelw@med.uni-marburg.de">oertelw@med.uni-marburg.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Wolfgang H. Oertel </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The author declares that he has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> WH Oertel is Hertie Senior Reserach Professor supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany. <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Oertel WH. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Oertel WH. Recent advances in treating Parkinson’s disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):260 (<a href="https://doi.org/10.12688/f1000research.10100.1" target=_blank>https://doi.org/10.12688/f1000research.10100.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 Mar 2017, <b>6</b>(F1000 Faculty Rev):260 (<a href="https://doi.org/10.12688/f1000research.10100.1" target=_blank>https://doi.org/10.12688/f1000research.10100.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 Mar 2017, <b>6</b>(F1000 Faculty Rev):260 (<a href="https://doi.org/10.12688/f1000research.10100.1" target=_blank>https://doi.org/10.12688/f1000research.10100.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d48991e146>Introduction</h2><div class=section><a name=d48991e149 class=n-a></a><h3 class=section-title>The decades of focus on the nigrostriatal system and dopamine replacement therapy</h3><p class="" id=d48991e154>Parkinson’s disease (PD) is a devastating disorder of the human nervous system and the second most common progressive chronic neurodegenerative disease. The three cardinal motor symptoms, akinesia in combination with either tremor at rest or rigidity (<a href="#ref-1">1</a> UK brain bank criteria), are—200 years after their description—still the basis of the clinical diagnosis. Up to 2016, we still have no treatment to slow down or even stop the progression of the disease. Available therapy is symptomatic. This article presents evidence that for the first time in history substances with a potentially disease-modifying effect for PD are under development and thus offer hope for the patient, the spouse, and the treating physician.</p><p class="" id=d48991e160>For more than 100 years, we know the neuropathological hallmarks of the disorder: the so-called Lewy bodies<sup><a href="#ref-2">2</a></sup> (proteinaceous intracytoplasmic inclusion bodies) containing aggregations of the protein alpha-synuclein<sup><a href="#ref-3">3</a></sup> and the loss of pigmented melanin containing neurons in the midbrain<sup><a href="#ref-4">4</a></sup>. The latter reflects the neurodegeneration of dopaminergic neurons in the substantia nigra (SN) leading to a marked dopamine deficit in the striatum. Since 1961<sup><a href="#ref-5">5</a></sup>, L-Dihydroxyphenylalanine (L-Dopa), a symptomatic dopamine replacement therapy, has been available for PD for more than 50 years. As L-Dopa, the precursor of dopamine—and subsequently ergot- and non-ergot dopamine agonists— are highly effective in reducing motor symptoms, PD was—for a long time—predominantly considered as a movement disorder. This focus was even enforced by the unraveling of the motor circuitry of the basal ganglia, of its imbalances in PD and the dramatic therapeutic effect of deep brain stimulation (DBS) of the subthalamic nucleus or the globus pallidus. These symptomatic therapeutic achievements may explain why the development of therapies for the wide range of disabling non-motor symptoms (NMSs) the patient with PD has throughout the course of the disease has been neglected. In addition, research efforts on the development of disease-modifying drugs were largely performed in acute toxin-induced rodent models (6-hydroxy-dopamine, or MPTP) and their neuroscientific results failed to translate into clinically successful drugs (reviewed in <a href="#ref-6">6</a>). Thus, apart from few cases of toxin-induced Parkinson syndromes, firm knowledge at the molecular level on the etiopathogenesis of PD was lacking until the year 1996.</p></div><div class=section><a name=d48991e183 class=n-a></a><h3 class=section-title>Genetic and neuropathological research revolutionize the understanding of Parkinson’s disease</h3><p class="" id=d48991e188>Two discoveries between 1996 and 2006 changed the field: <div class=list><a name=d48991e190 class=n-a></a><ul style="list-style-type: none"><li><p id=d48991e197><span class=label>1) </span> The description of a mutation in the gene for the protein alpha-synuclein, causing a rare form of autosomal-dominant PD<sup><a href="#ref-7">7</a></sup>; the discovery that gene duplication of this gene for normal wild-type alpha-synuclein (that is, the presence of three alleles instead of two alleles leading to a production of 150% of normal alpha-synuclein) causes PD; and the presence of pathological alpha-synuclein-aggregations in the Lewy bodies in the SN<sup><a href="#ref-3">3</a></sup>.</p></li><li><p id=d48991e214><span class=label>2) </span> The publication of the Braak staging of PD<sup><a href="#ref-8">8</a></sup> combined with the “dual hit theory”<sup><a href="#ref-9">9</a></sup> (see below) proposing that the manifestation of motor PD symptoms is a late-stage phenotype preceded for years, if not decades, by three prodromal stages (<a href="#f2">Figure 2</a>).</p></li></ul></div> </p></div><div class=section><a name=d48991e232 class=n-a></a><h3 class=section-title>The shift from research on symptomatic therapy to the search for Parkinson’s disease-modifying therapy</h3><p class="" id=d48991e237>Based on these findings, the majority of cases with PD (the so-called idiopathic form of PD) were assumed to present an alpha-synucleinopathy. Drug development shifted its focus from transmitters, transmitter-related receptor agonists and antagonists, and transmitter-synthesizing and -degrading enzymes to the protein chemistry, synthesis, transport, aggregation, and degradation of alpha-synuclein and other proteins related to neurodegenerative disorders, such as MAP-Tau or beta-amyloid. A now-20-year-long effort in neuroscience and drug development appears to provide the first results.</p><p class="" id=d48991e240>This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor PD symptoms, (2) the still-limited attempts to provide symptomatic therapy for NMSs in PD, and (3) the advances in the development and clinical testing of compounds, which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials, which reflect the progression in prodromal stages of PD, such as in rapid eye movement (REM) sleep behavior disorder (RBD), the most specific prodromal stage of PD - a methodological challenge to be met in the future.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d48991e247>Present therapy 2017</h2><div class=section><a name=d48991e250 class=n-a></a><h3 class=section-title>Present therapy (2017) available for Parkinson’s disease is symptomatic</h3><p class="" id=d48991e255>In 1960, the lack of dopamine in brains of patients with PD was discovered, and the first rationally derived therapy was introduced to neurology when the “miraculous” improvement of the motor symptoms under therapy with intravenous L-Dopa, the blood-brain barrier-passing precursor of dopamine<sup><a href="#ref-5">5</a></sup>, was reported. Since then, generations of medical students have learned that the symptoms of PD are caused by a dopamine deficit, leading to an imbalance of the motor, cognitive, and emotional loops in the basal ganglia circuitry. Although hard to believe, 56 years after its discovery, L-Dopa is still the gold standard for any of the available multiple symptomatic therapies for PD. Owing to L-Dopa’s short plasma half-life (1–2 hours), repeated intake results in a pulsatile plasma profile. With progressing neurodegeneration of the nigrostriatal pathway, the storage capacity of the central nervous system (CNS) for L-Dopa and dopamine declines, thus in the intermediate to advanced stages of PD, the duration of the central L-Dopa effect will mimic the pulsatile plasma profile of the medication. The longer the disease lasts, the more patients with PD experience “motor complications”, consisting of motor fluctuations (a change between phases of akinesia (OFF: no or low, therapeutically ineffective L-Dopa level) and normal movement (ON: therapeutically effective L-Dopa level) and also of an excess of movements (choreatic “dyskinesia”) at the peak of the L-Dopa curve in the blood and thus in the CNS. To delay or ameliorate these L-Dopa therapy-associated motor complications, several other classes of drugs are available to be prescribed before the use of or in combination with L-Dopa. The L-Dopa effect can be enhanced and prolonged by (1) the combination with peripheral inhibitors—(a) of the degrading enzyme L-DOPA-decarboxylase (that is, benserazide, carbidopa – standard combination) and (b) of the degrading enzyme catechol-<i>O</i>-methyl transferase (COMT) (that is, by adding the short-acting COMT-inhibitor entacapone or intermediate-acting tolcapone)—or with (2) centrally active inhibitors of the degrading enzyme monoamino-oxidase B (MAO-B), such as selegiline or rasagiline. As an advanced therapeutic option, L-Dopa emulsion can be applied by an external pump via a percutaneous tubing into the jejunal cavity in order to provide a nearly constant continuous supply of L-Dopa to the blood and thus to the CNS. In addition, physicians have at hand five non-ergot dopamine agonists, mainly of the dopamine-2-receptor type: pramipexole, ropinirole and piribedil (only registered in Europe) for oral intake, rotigotine by 24-hour transdermal application, and apomorphine, which needs a parenteral administration (that is, subcutaneous: bolus or pump assisted infusion). As pramipexole and ropinirole are available—besides the standard release formulation—as slow release preparations, four non-ergot agonists can offer continuous dopamine-2-receptor stimulation for a 24-hour period. Ergot dopamine agonists are indicated only as a second-line choice, as they run the risk of inducing fibrosis of the heart valves or the retroperitoneum. Furthermore, the <i>N</i>-methyl-D-aspartate (NMDA) (glutamate subtype) receptor antagonist amantadine is considered to improve PD motor symptoms and at the same time to reduce motor complications, especially dyskinesia.</p><p class="" id=d48991e268>Finally, numerous pharmacotherapies are available for individual NMSs<sup><a href="#ref-10">10</a></sup> though mostly by employing a given compound approved to treat the symptom or disease per se and not a particular symptom as part of the spectrum of NMSs in PD (for example, using an antidepressant for depression in PD; see below and Seppi <i>et al</i>.<sup><a href="#ref-11">11</a></sup>)</p><p class="" id=d48991e282>The introduction of DBS further increased the therapeutic options for patients with PD. The pacemaker assisted stimulation of stereotactically, to the millimeter precisely placed electrodes—either in the subthalamic nucleus or the internal part of the globus pallidus—allows reduction of the imbalance in the above-mentioned motor circuitry of the basal ganglia<sup><a href="#ref-12">12</a></sup>. This procedure has been shown to be effective not only in very advanced PD patients but also in PD patients, who just have started to develop motor complications<sup><a href="#ref-13">13</a></sup>. DBS in turn allows one to decrease the amount of pharmacotherapy and this measure leads to less motor (see above) or neuropsychiatric (see below) adverse effects or both, which can occur with the above-mentioned combination of different pharmaceuticals in all stages of PD.</p><p class="" id=d48991e293>In addition, in the last decade, an increasing number of partly well-designed and conducted studies have investigated the effect of non-medical/non-surgical supportive “activating” therapies; these include physical exercise, physiotherapy (more than 30 trials)<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a>,<a href="#ref-82">82</a>,<a href="#ref-83">83</a></sup>, dance interventions (4 trials), and logopedic training of dysphagia (2 trials) on the neurological symptoms of PD patients and their quality of life (comprehensively reviewed in <a href="#ref-15">15</a>,<a href="#ref-16">16</a>). Despite all of these achievements until today, we still treat PD at an entirely symptomatic level<sup><a href="#ref-17">17</a></sup>.</p></div><div class=section><a name=d48991e320 class=n-a></a><h3 class=section-title>The challenge of treating motor AND non-motor symptoms</h3><p class="" id=d48991e325>In summary, neurologists, and especially movement disorder experts, can choose from a large number of compounds to treat the motor symptoms in PD effectively for several years, if not decades. In addition, owing to advances in the field of internal medicine, the surgical disciplines, and anesthesia, patients with PD live longer, but with a price or rather trade off to find the optimal therapeutic balance between motor- and non-motor symptoms with a minimum of adverse effects:</p><p class="" id=d48991e328>1) With increasing age and duration of PD, gait problems—non-responsive to dopamimetic therapy, combined with the increased risk to fall and to incur fractures—and other NMSs appear. These NMSs include autonomic dysfunctions (for example, urinary incontinence and severe obstipation), sleep impairment, pain syndromes, and most important, neuropsychiatric symptoms, including depression, impulse control disorders, punding, hallucinations, overt psychosis (in part induced by dopamimetic therapy), and cognitive impairment progressing to dementia<sup><a href="#ref-10">10</a></sup>. The NMSs substantially impair the quality of life not only of the PD-patient but also of their family. Thus, in the very advanced stages, the family and the physician face—in many cases—a disoriented, often demented PD patient, who either is mobile, if not hypermobile (dyskinetic), and may hallucinate and even endanger him- or herself or others or who is akinetic-rigid.</p><p class="" id=d48991e335>2) With increasing age, the extent of comorbidity increases (for example, orthopedic syndromes, diabetes mellitus and metabolic syndrome<sup><a href="#ref-16">16</a></sup>, heart failure, and stroke). This comorbidity in patients with PD is a major challenge in the ambulatory care. Hardly any studies have been performed to assess the efficacy, benefit-risk ratio, and tolerability of available symptomatic PD therapy in these real-life “wild-type” PD patients.</p><p class="" id=d48991e342>Thus, the weight of therapeutic need has shifted from “just” making or keeping the PD patient mobile to the challenge to fine-tune a therapeutic combination of drugs for (1) the treatment of motor and non-motor symptoms, (2) motor and non-motor complications (including hallucinations, or psychosis induced by dopamimetic therapy, particularly in cognitively impaired patients with PD), and (3) treatment that, in accordance with other medical treatments and care, is acceptable to the patient and the caring partner.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d48991e349>New developments in Parkinson’s disease therapy</h2><p class="" id=d48991e352>With this situation in mind, efforts over the last 20 years to develop new therapies for PD can be divided in two categories: (1) improving symptomatic therapy of (1a) motor and (1b) non-motor symptoms and (2) addressing potential causes of PD, with a focus on the protein alpha-synuclein, its chemistry, synthesis, aggregation, degradation, and interaction with other proteins in order to develop a disease modifying treatment.</p><div class=section><a name=d48991e355 class=n-a></a><h3 class=section-title>New developments in symptomatic therapy of motor symptoms</h3><p class="" id=d48991e360>To improve the available symptomatic therapy for motor symptoms, several drugs have recently been approved or are still under testing. These developments include the improvement of the pump device for infusing L-Dopa in the jejunal cavity (likely available in 2017 or 2018<sup><a href="#ref-18">18</a></sup>) and the approval of a long-acting (5- to 6-hour duration of action) L-Dopa (currently available in the USA under the tradename Rytary<sup><a href="#ref-19">19</a>–<a href="#ref-25">25</a></sup>; <a href="#T1">Table 1</a>). The latter compound is absorbed not only in the duodenum but also in the ileum; thus, its absorption may depend less on food intake/diet<sup><a href="#ref-26">26</a></sup>. Surprisingly little information is available about its use in daily practice, and no active comparator trial (for example, against the intrajejunal L-Dopa-infusion or DBS) is under way or in planning in PD patients with motor complications.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. New developments in symptomatic therapy of Parkinson’s disease.</h3><p id=d48991e391><b>Part A. For motor symptoms and motor complications by means of dopaminergic mode of action: new compound or new formulation, mode of action (fully or in part) provided by other approved compound</b>.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d48991e397 class=n-a></a><thead><a name=d48991e399 class=n-a></a><tr><a name=d48991e401 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e403 class=n-a></a>Compound/<br class=br><i>Trade name</i><br class=br>(Company [C],<br class=br>Sponsor [S])</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e413 class=n-a></a>Indication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e416 class=n-a></a>Mode of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e419 class=n-a></a>Phase of<br class=br>development</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e424 class=n-a></a>Commentary and<br class=br>approved dose</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e430 class=n-a></a>Reference</th></tr></thead><tbody><a name=d48991e435 class=n-a></a><tr><a name=d48991e437 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e439 class=n-a></a><b>Melevodopa/</b><br class=br><b>Carbidopa</b><br class=br><i>Sirio</i><br class=br>(Chiesi [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e451 class=n-a></a>Motor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e454 class=n-a></a>Modified form of<br class=br>L-Dopa soluble<br class=br>tablet</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e461 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e464 class=n-a></a>Marketed in Italy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e468 class=n-a></a>Zangaglia <i>et al</i>. 2010<sup><a href="#ref-85">85</a></sup><br class=br>Fasano <i>et al</i>. 2014<sup><a href="#ref-86">86</a></sup></td></tr><tr><a name=d48991e486 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e488 class=n-a></a><b>Opicapone</b><br class=br><i>Ongentys</i><br class=br>(BIAL [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e497 class=n-a></a>Motor<br class=br>wearing-off</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e502 class=n-a></a>COMT-inhibitor,<br class=br>long-acting,<br class=br>add-on to L-Dopa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e509 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e512 class=n-a></a>Reimbursed in EU<br class=br><b>50 mg/day</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e519 class=n-a></a>Ferreira <i>et al</i>. 2015<sup><a href="#ref-33">33</a></sup><br class=br>Ferreira <i>et al</i>. 2015<sup><a href="#ref-87">87</a></sup><br class=br>Rocca <i>et al</i>. 2016<sup><a href="#ref-35">35</a></sup><br class=br>Fabbri <i>et al</i>. 2016<sup><a href="#ref-34">34</a></sup></td></tr><tr><a name=d48991e554 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e556 class=n-a></a><b>Safinamide</b><br class=br><i>Xadago</i><br class=br>(Zambon [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e565 class=n-a></a>Motor<br class=br>wearing-off</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e570 class=n-a></a>MAO-B-inhibitor,<br class=br>glutamate<br class=br>modulator, add-on<br class=br>to L-Dopa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e579 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e582 class=n-a></a>Reimbursed in EU,<br class=br>active comparator<br class=br>study to other<br class=br>MAO-B-<br class=br>inhibitors not available<br class=br><b>50 or 100 mg/day</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e597 class=n-a></a>Stocchi + Torti 2016<sup><a href="#ref-32">32</a></sup><br class=br>Cattaneo <i>et al</i>. 2016<sup><a href="#ref-31">31</a></sup><br class=br>Borgohain <i>et al</i>. 2014<sup><a href="#ref-29">29</a></sup><br class=br>Borgohain <i>et al</i>. 2014<sup><a href="#ref-30">30</a></sup><br class=br>Schapira <i>et al</i>. 2013<sup><a href="#ref-28">28</a></sup><br class=br>Stocchi <i>et al</i>. 2012<sup><a href="#ref-27">27</a></sup></td></tr><tr><a name=d48991e646 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e648 class=n-a></a><b>“XP066”</b><br class=br><i>Rytary</i><br class=br>(Impax [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e657 class=n-a></a>Motor<br class=br>wearing-off</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e662 class=n-a></a>L-Dopa/<br class=br>Carbidopa (4/1)<br class=br>long-acting,<br class=br>extended release</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e671 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e674 class=n-a></a>Reimbursed in USA<br class=br><b>95, 145, 195, or 245 mg</b><br class=br><b>L-Dopa capsules</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e684 class=n-a></a>Yao <i>et al</i>. 2016<sup><a href="#ref-25">25</a></sup><br class=br>Mao + Modi 2016<sup><a href="#ref-24">24</a></sup><br class=br>Waters <i>et al</i>. 2015<sup><a href="#ref-22">22</a></sup><br class=br>Hsu <i>et al</i>. 2015<sup><a href="#ref-23">23</a></sup><br class=br>Stocchi <i>et al</i>. 2014<sup><a href="#ref-21">21</a></sup><br class=br>Pahwa <i>et al</i>. 2014<sup><a href="#ref-20">20</a></sup><br class=br>Hauser <i>et al</i>. 2013<sup><a href="#ref-19">19</a></sup></td></tr></tbody></table></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3></h3><p class=first id=d48991e748><b>Part B. For motor symptoms, motor complications or non-motor symptoms by means of a non-dopaminergic mode of action: new compounds or new formulation</b>.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d48991e754 class=n-a></a><thead><a name=d48991e756 class=n-a></a><tr><a name=d48991e758 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e760 class=n-a></a>Compound</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e763 class=n-a></a>Indication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e766 class=n-a></a>Mode of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e769 class=n-a></a>Phase of<br class=br>development</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e774 class=n-a></a>Commentary</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e778 class=n-a></a>Reference</th></tr></thead><tbody><a name=d48991e783 class=n-a></a><tr><a name=d48991e785 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e787 class=n-a></a><b>Amantadine</b><br class=br>Extended release<br class=br>(Adamas [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e795 class=n-a></a>Motor<br class=br>dyskinesia<br class=br>off-time</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e802 class=n-a></a>NMDA-receptor<br class=br>antagonist,<br class=br>long-acting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e809 class=n-a></a>Phase III<br class=br>completed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e814 class=n-a></a>Likely to be registered<br class=br>2017 or 2018 as<br class=br><b>340 mg/day</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e823 class=n-a></a>Pahwa <i>et al</i>. 2016<sup><a href="#ref-37">37</a></sup><br class=br>Pahwa <i>et al</i>. 2015<sup><a href="#ref-36">36</a></sup></td></tr><tr><a name=d48991e841 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e843 class=n-a></a><b>Droxidopa</b><br class=br>L-Threo-3,4-<br class=br>Dihydroxy-Phenylserine<br class=br><i>Northera</i><br class=br>(Lundbeck [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e856 class=n-a></a>Motor and<br class=br>Non-Motor<br class=br>freezing<br class=br>Neurogenic<br class=br>orthostatic<br class=br>hypotension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e869 class=n-a></a>Noradrenaline<br class=br>precursor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e874 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e876 class=n-a></a><br class=br>Approved in Japan,<br class=br>approved in USA<br class=br><b>3×100 mg/capsule</b><br class=br><b>max. 3×6 capsules</b><br class=br>(max. daily dose<br class=br>1,800 mg)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e893 class=n-a></a>Hauser <i>et al</i>. 2014<sup><a href="#ref-56">56</a></sup><br class=br>Espay <i>et al</i>. 2014<sup><a href="#ref-57">57</a></sup><br class=br>Mathias <i>et al</i>. 2001<sup><a href="#ref-55">55</a></sup></td></tr><tr><a name=d48991e920 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e922 class=n-a></a><b>Istradefylline</b><br class=br><i>Nouriast</i><br class=br>(Kyowa-Hakko-<br class=br>Kirin [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e933 class=n-a></a>Motor<br class=br>wearing-off</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e938 class=n-a></a>Adenosine<br class=br>2A receptor<br class=br>antagonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e945 class=n-a></a>Phase III<br class=br>positive<br class=br>Phase III<br class=br>ongoing in EU</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e954 class=n-a></a>Approved in Japan<br class=br><b>20 mg/once daily</b><br class=br>(40 mg/daily possible)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e963 class=n-a></a>Vorovenci + Antonini<br class=br>2015<sup><a href="#ref-43">43</a></sup><br class=br>Kondo <i>et al</i>. 2015<sup><a href="#ref-40">40</a></sup><br class=br>Pinna 2014<sup><a href="#ref-44">44</a></sup><br class=br>Mizuno <i>et al</i>. 2013<sup><a href="#ref-39">39</a></sup><br class=br>Pourcher <i>et al</i>. 2012<sup><a href="#ref-42">42</a></sup><br class=br>Factor <i>et al</i>. 2010<sup><a href="#ref-41">41</a></sup><br class=br>Mizuno <i>et al</i>. 2010<sup><a href="#ref-38">38</a></sup></td></tr><tr><a name=d48991e1019 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1021 class=n-a></a><b>Tozadenant</b><br class=br>(Biotie [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1027 class=n-a></a>Motor<br class=br>dyskinesia<br class=br>wearing-off</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1034 class=n-a></a>Adenosine<br class=br>2A receptor<br class=br>antagonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1041 class=n-a></a>Phase III<br class=br>ongoing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1046 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1049 class=n-a></a>Michel <i>et al</i>. 2015<sup><a href="#ref-88">88</a></sup><br class=br>Hauser <i>et al</i>. 2014<sup><a href="#ref-89">89</a></sup><br class=br>Perez-Lloret + Morello<br class=br>2014<sup><a href="#ref-90">90</a></sup></td></tr><tr><a name=d48991e1075 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1077 class=n-a></a><b>Pimavanserin</b><br class=br><i>Nuplazid</i><br class=br>(Acadia [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1086 class=n-a></a>Non-motor<br class=br>psychosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1091 class=n-a></a>5HT2A inverse<br class=br>agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1096 class=n-a></a>Phase III<br class=br>positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1101 class=n-a></a>Approved in USA<br class=br><b>2x17 mg/ once daily</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1108 class=n-a></a>Cummings <i>et al</i>. 2014<sup><a href="#ref-53">53</a></sup><br class=br>Hacksell <i>et al</i>. 2014<sup><a href="#ref-91">91</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d48991e1130 class=n-a></a><p id=d48991e1132> Modified from Oertel and Schulz<sup><a href="#ref-17">17</a></sup> (2016).</p></div></div></div><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3></h3><p class=first id=d48991e1146><b>Part C. For motor complications or non-motor symptoms by means of a non-dopaminergic mode of action: drug approved in another indication, now tested in Parkinson’s disease</b>.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d48991e1152 class=n-a></a><thead><a name=d48991e1154 class=n-a></a><tr><a name=d48991e1156 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1158 class=n-a></a>Compound</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1161 class=n-a></a>Indication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1164 class=n-a></a>Mode of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1167 class=n-a></a>Phase of<br class=br>development</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1172 class=n-a></a>Commentary</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1176 class=n-a></a>Reference</th></tr></thead><tbody><a name=d48991e1181 class=n-a></a><tr><a name=d48991e1183 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1185 class=n-a></a><b>Donepezil</b><br class=br>Eisai (C)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1191 class=n-a></a>Non-motor<br class=br>falls, gait<br class=br>disorder,<br class=br>dementia in<br class=br>Parkinson’s<br class=br>disease (PD)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1204 class=n-a></a>Acetylcholin-<br class=br>esterase-<br class=br>inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1211 class=n-a></a>Phase IIIb<br class=br>ongoing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1216 class=n-a></a>Approved<br class=br>for therapy<br class=br>of Alzheimer<br class=br>dementia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1226 class=n-a></a>Chung <i>et al</i>. 2010<sup><a href="#ref-92">92</a></sup><br class=br>Ravina <i>et al</i>. 2005<sup><a href="#ref-93">93</a></sup></td></tr><tr><a name=d48991e1244 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1246 class=n-a></a><b>Duloxetine</b><br class=br><i>Cimbalta, Xeristar</i><br class=br>(University of<br class=br>Toulouse [S])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1257 class=n-a></a>Non-motor<br class=br>pain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1262 class=n-a></a>SSNRI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1265 class=n-a></a>Phase III<br class=br>ongoing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1270 class=n-a></a>Approved for<br class=br>therapy of<br class=br>pain and of<br class=br>depression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1280 class=n-a></a></td></tr><tr><a name=d48991e1283 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1285 class=n-a></a><b>Oxycodone/</b><br class=br><b>Naloxone</b><br class=br><i>Targin</i><br class=br>(MundiPharma [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1297 class=n-a></a>Severe pain<br class=br>syndrome in PD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1302 class=n-a></a>Opioid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1305 class=n-a></a>Phase III<br class=br>positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1310 class=n-a></a>Approved for<br class=br>therapy of pain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1316 class=n-a></a>Trenkwalder <i>et al</i>. 2015<sup><a href="#ref-54">54</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d48991e1330 class=n-a></a><p id=d48991e1332> Modified from Oertel and Schulz<sup><a href="#ref-17">17</a></sup> (2016).</p></div></div></div><p class="" id=d48991e1343>To prolong and enhance the action of L-Dopa, the new reversible MAO B-inhibitor safinamide<sup><a href="#ref-27">27</a>–<a href="#ref-32">32</a></sup>—with the claim that this compound also influences glutamatergic transmission—and the long-lasting COMT inhibitor opicapone<sup><a href="#ref-33">33</a>–<a href="#ref-35">35</a></sup> have been approved (both at present in Europe). An extended-release (24-hour long-acting) formulation of amantadine has been recently reported to markedly reduce the severity and extent of L-Dopa-induced dyskinesia and also to reduce off-time<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>.</p><p class="" id=d48991e1367>Based on the restricted localization of adenosine-2A-receptors in the striatopallidal indirect pathway of the basal ganglia circuitry, adenosine-2A-receptor antagonists have been developed for the therapy of motor fluctuations and are now approved in Japan (istradefylline, tradename Nouriast<sup><a href="#ref-38">38</a>–<a href="#ref-40">40</a></sup>, whereas registration trials<sup><a href="#ref-41">41</a>–<a href="#ref-43">43</a></sup> in Europe with this compound and clinical testing with a second compound of this class (tozadenant) are ongoing (<a href="#T1">Table 1</a>).</p><p class="" id=d48991e1387>The development of a third compound of this class, preladenant, was stopped because of negative results in phase III trials<sup><a href="#ref-44">44</a></sup>.</p><p class="" id=d48991e1394>Likewise employing the primary endpoint of “reduction of L-Dopa induced dyskinesia”, the results of clinical phase III trials with the metabotropic-glutamate-receptor-5-antagonist (mavoglurant)<sup><a href="#ref-45">45</a>–<a href="#ref-48">48</a></sup> and the nicotine-alpha-7-partial agonist AQW051<sup><a href="#ref-49">49</a></sup> were negative and thus their development stopped, whereas the clinical testing of glutamate-receptor-4-antagonists and allosteric modulators of the metabotropic-glutamate-receptor-5—employing the same endpoint (reduction of dyskinesia)—are ongoing.</p><p class="" id=d48991e1408>For the field of DBS, improved hardware and software (rechargeable battery, multipolar electrodes) now offer a higher flexibility and precision to individually target the different motor symptoms (akinesia, rest tremor) and to avoid stimulation-related side effects (reviewed in <a href="#ref-50">50</a>–<a href="#ref-52">52</a>).</p></div><div class=section><a name=d48991e1418 class=n-a></a><h3 class=section-title>New developments in symptomatic therapy of non-motor symptoms</h3><p class="" id=d48991e1423>In 2011, the International Movement Disorder Society published a comprehensive evidence-based medicine review on the therapy of NMSs of PD<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. On one hand, it provides profound guidance for how to treat the individual NMSs in PD. On the other hand, this review demonstrates how few clinical randomized placebo or active comparator multicenter prospective trials of “evidence-based medicine class I and class II” existed thus far for the therapy of NMSs in PD—in contrast to the numerous prospective multicenter trials on motor symptoms and motor complications. Since then, increased efforts in this field have led to the approval of new therapies. For the treatment of dopamimetic-induced psychosis in PD, the 5HT2A inverse agonist pimavanserin has been approved in the USA<sup><a href="#ref-53">53</a></sup>; thus, for the first time, an alternative to the currently employed antipsychotic compounds quetiapine or clozapine is available—although an active comparator trial between pimavanserin and, for example, clozapine is missing. In regard to severe pain syndromes, the slow-release preparation of oxycodone/naloxone has been successfully tested in PD<sup><a href="#ref-54">54</a></sup>. Furthermore, the precursor of noradrenaline droxidopa, also known as L-threo-DOPS, has been approved for the treatment of neurogenic orthostatic hypotension, one of the troubling autonomic symptoms in advanced PD and even more so in multiple system atrophy (MSA), another alpha-synucleinopathy<sup><a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>. In regard to DBS, a large recent study has shown beneficial effects of this neurosurgical procedure on NMSs<sup><a href="#ref-58">58</a></sup>. Given the major impact of NMS and therapy-related non-motor complications on the quality of life for PD patients and their partners, this field clearly needs priority in future clinical trials.</p><p class="" id=d48991e1452>In summary, these compounds and techniques allow fine tuning of the available symptomatic therapy of motor and in part of NMSs in PD. However, they do not represent a major innovation. A true, highly needed innovation would be a compound with disease-modifying properties in order to slow down, if not stop, the progressive pathophysiology of PD (that is, most likely the spreading of the alpha-synucleinopathy in the central, peripheral, autonomic, and gastrointestinal nervous system of patients with PD).</p></div><div class=section><a name=d48991e1456 class=n-a></a><h3 class=section-title>The revolution in genetic research in Parkinson’s disease</h3><p class="" id=d48991e1461>In 1997, the world of PD research changed. For the first time, though very rare, an autosomal dominant mutation (termed <i>PARK1</i>) responsible for the protein alpha-synuclein was described<sup><a href="#ref-7">7</a></sup>. By 2016, at least eight monogenic causes for PD are known. The autosomal dominant forms relate either to a mutation of alpha-synuclein or to LRRK2, whereas autosomal recessive forms (<i>PARK2</i>, <i>PINK1</i>, <i>DJ1</i>) cause mitochondrial dysfunction. The third major discovery was the fact that 3–7% of patients with idiopathic PD carry a heterozygous mutation for the gene glucocerebrosidase A. Genome-wide association studies have confirmed—besides the role of alpha-synuclein—the importance of the microtubule-associated protein tau (MAPT) in the etiopathogenesis of PD. Furthermore, at least 28 genetic risk (susceptibility) factors have been identified, and it is likely that this number will further increase (reviewed in <a href="#ref-59">59</a>). These discoveries have already had a major impact on the development of new therapies, especially in regard to potentially disease-modifying compounds—as will be discussed in relation to the alpha-synuclein “spreading hypothesis” below.</p></div><div class=section><a name=d48991e1486 class=n-a></a><h3 class=section-title>The Braak staging of Parkinson’s disease, the spreading hypothesis, the search for prodromal stages of Parkinson’s disease: advantages and limitations</h3><p class="" id=d48991e1491>Shortly after the discovery that a mutation of alpha-synuclein causes PD, alpha-synuclein aggregates were identified in the Lewy bodies in the post-mortem SN samples of patients with idiopathic PD<sup><a href="#ref-3">3</a></sup>. Therefore, the majority of patients with idiopathic PD are now considered to suffer from an alpha-synucleinopathy. Based on the distribution of these Lewy bodies in the nervous system, Braak <i>et al</i>.<sup><a href="#ref-8">8</a></sup> postulated that most likely PD—as it is defined with its motor symptoms by the neurologist—is a late-stage phenotype of a disease which has been going on for decades.</p></div><div class=section><a name=d48991e1506 class=n-a></a><h3 class=section-title>The Braak staging of Parkinson’s disease: the spreading hypothesis</h3><p class="" id=d48991e1511>The Braak<sup><a href="#ref-8">8</a></sup> staging hypothesis, combined with the “dual hit theory”<sup><a href="#ref-9">9</a></sup>, proposes that PD starts either in the olfactory bulb and related areas or in the gastrointestinal system. Thus, a pathological agent either would retrogradely reach the SN via an only recently discovered connection between the olfactory bulb and the SN<sup><a href="#ref-60">60</a></sup> or may move retrogradely from the gastrointestinal system up to the dorsal motor nucleus of the vagal nerve, would then—in a caudorostral ascending direction—propagate upwards in the brainstem reaching the locus coeruleus complex, and over the next 5 to 10 years finally affect the SN (see <a href="#f2">Figure 2</a> and its legend).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure1.gif"><img alt="43a05b5b-c0cc-4e95-b416-64f1259abf21_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure1.gif"></a><div class=caption><h3>Figure 1. Scheme of a dopaminergic synapse with the different sites of actions for symptomatic Parkinson’s disease therapy.</h3><p id=d48991e1539>COMT, catechol-O-methyl-transferase (inhibitor: entacapone, opicapone<sup>a</sup>, tolcapone); D1, D1 receptor: agonist (new compound in phase III); D2, D2/D3 receptor (non-ergot agonist: apomorphine, piribedil, pramipexole, ropinirole, rotigotine); D2b, presynaptic D2-autoreceptor; DDC, L-DOPA-decarboxylase; DOPAC, dihydroxyphenylacetic acid; L-DOPA<sup>a</sup>, L-dihydroxyphenylalanine (extended release); MAO-A, monoaminooxidase A; MAO-B, monoaminooxidase B (inhibitor: rasagiline, safinamide<sup>a</sup>, selegiline); TH, tyrosine hydroxylase; 3MT, 3 methoxy-tyramine; *, effect of L-DOPA (converted into dopamine); **, effect of dopamine agonists (mimics dopamine at D1 or D2/3 receptor and at D2b autoreceptor); ***, effect of MAO-B-inhibitor (blocks centrally degradation of dopamine, enhances and prolongs dopamine action); ****, effect of COMT-inhibitor (blocks peripherally degradation of L-DOPA, enhances and prolongs presence of L-DOPA in blood and thus enhances and prolongs action of central dopamine action); <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure3.gif"><img alt="43a05b5b-c0cc-4e95-b416-64f1259abf21_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure3.gif"></a>, vesicle; the round structure represents the symbol for the vesicle <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure4.gif"><img alt="43a05b5b-c0cc-4e95-b416-64f1259abf21_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure4.gif"></a>, the arrow represents the uptake mechanism - dopamine reuptake mechanism. <sup>a</sup>Recently approved for therapy of Parkinson’s disease (<a href="#T1">Table 1</a>).</p></div></div><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure2.gif"><img alt="43a05b5b-c0cc-4e95-b416-64f1259abf21_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10881/43a05b5b-c0cc-4e95-b416-64f1259abf21_figure2.gif"></a><div class=caption><h3>Figure 2. Braak’s hypothesis: staging of Parkinson’s disease.</h3><p id=d48991e1576>This simplified hypothetical scheme shows how Parkinson’s disease may develop based on the hypothesis of the Braak staging<sup><a href="#ref-8">8</a></sup> and the “dual hit theory”<sup><a href="#ref-9">9</a></sup>. OB, olfactory bulb, SLD, sublaterodorsal nucleus of the subcoeruleus/coeruleus complex; lesion of the SLD leads to rapid-eye-movement sleep behavior disorder (RBD). The orange line illustrates the afferent connection from the substantia nigra to the olfactory bulb. The α-synuclein (aSYN) aggregates (red-circled icon) may retrogradely spread from the GIT via the dorsal motor nucleus of the vagal nerve to the locus coeruleus and subsequently ascend to the substantia nigra (Hit 1). It is discussed that the later propagation may either take place by means of direct anterograde transport (thin light blue arrow with question mark – from the LC to the SN) or retrograde transport from the LC to the SN (empty arrow with question mark), or via an intermediate structure (orange circle) such as the amygdala complex (asterix). Likewise the aSYN aggregates (red-circled icon) may retrogradely spread from the OB to the substantia nigra (Hit 2). Dopamine transporter single-photon emission computed tomography (DAT-SPECT): On the right side, images of the striatal presynaptic terminals of the nigrostriatal pathway are visualized by DAT-SPECT. In Braak stage 1, the DAT-SPECT is normal. In Braak stage 2, the DAT-SPECT is still normal (Locus coeruleus −). In Braak stage 3, the nigrostriatal pathway is partially degenerated but less than necessary to cause parkinsonian motor symptoms and signs. The image shows a partial loss of the nigrostriatal dopaminergic terminals in the dorsolateral aspect of the striatum (Locus coeruleus +). The red line indicates the threshold for the extent of the nigrostriatal lesion associated with parkinsonian motor symptoms. In Braak stage 4, the loss of the nigrostriatal terminals in the striatum is so marked that the patient will experience parkinsonian motor symptoms and signs.</p></div></div><p class="" id=d48991e1591>There is considerable clinical and experimental evidence in favor of this “dual hit theory”<sup><a href="#ref-9">9</a></sup>, although it is not proven beyond doubt and likely not to be applicable for a minority of patients with PD. That alpha-synuclein can spread in the human nervous system was reported in 2008<sup><a href="#ref-61">61</a></sup>: Lewy bodies arise in healthy fetal mesencephalic cells several years after their transplantation into the striatum of patients with PD. This fact is most likely explained by trans-synaptic spreading of pathological alpha-synuclein from the host neurons into the donor neurons. Intense research in experimental animal models of PD is ongoing to understand the pathogenic role of the different forms (such as monomers versus oligomers versus fibrils) of aggregated alpha-synuclein and to analyze the mechanism behind the postulated “prion-like” spreading of alpha-synuclein. For example, research in a transgenic alpha-synuclein-overexpressing and germ-free mouse model of PD recently demonstrated a marked effect of the gut microbiota on the development of the alpha-synucleinopathy and the manifestation of motor impairment, thus strengthening the hypothesis that the gastrointestinal system can play a role in the etiopathogenesis or progression (or both) of PD<sup><a href="#ref-62">62</a></sup>.</p></div><div class=section><a name=d48991e1607 class=n-a></a><h3 class=section-title>Clinical research on prodromal Parkinson’s disease</h3><p class="" id=d48991e1612>In the clinical situation, manifest PD—according to Braak <i>et al</i>.<sup><a href="#ref-8">8</a></sup>—is preceded by years, if not decades, by prodromal phases. To screen for prodromal (premotor) phases, the NMS hyposmia, constipation, depression, and the sleep-dream phase disorder RBD (REM sleep behavior disorder) are now considered prodromal indicators. Whereas the first three are sensitive but not specific, RBD is now accepted as the most specific phenotype of the PD prodromal phases with a risk of more than 80% to convert into PD, or dementia with Lewy bodies (DLB) or less frequently into multiple system atrophy(MSA)—in 10 to 15 years<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. Similar research on prodromal stages takes place with “at risk relatives” of Parkinson patients, who are either heterozygous for the <i>LRRK2</i> gene or are homozygous for one of the autosomal-recessive genes for a mitochondrial dysfunction in PD (<i>PAKR2</i>, <i>PINK1</i>, <i>DJ1</i>; for a comprehensive review on Mendelian and non-Mendelian inheritance of PD, see <a href="#ref-59">59</a>) or possess a mutation of the gene for glucocerebrosidase 1 (<i>GBA1</i>) and thus are classified as PD-GBA1<sup><a href="#ref-65">65</a></sup>.</p></div><div class=section><a name=d48991e1653 class=n-a></a><h3 class=section-title>The Braak hypothesis: advantages and limitations</h3><p class="" id=d48991e1658>The advantage of the Braak hypothesis is that it can clinically be tested. By carefully screening and following up patients at risk for PD, such as patients with hyposmia or RBD or with both<sup><a href="#ref-66">66</a></sup>, clinicians can identify a subgroup of patients with prodromal PD who present with and develop the sequence of symptoms related to the postulated prodromal PD stages. This type of study may allow us to discover endpoints for future neuroprotective trials in prodromal PD.</p><p class="" id=d48991e1665>Limitations of the Braak hypothesis are related to post-mortem analysis of PD brains<sup><a href="#ref-67">67</a></sup>: they show, for example, that the density of Lewy bodies in the medullary areas is lower than in the cortex. In addition, a similar distribution of Lewy neuropathology is observed in patients with incidental Lewy body disease (that is, individuals with the hallmark Lewy pathology in brain, who did not present when alive with motor Parkinson features).</p><p class="" id=d48991e1672>This observation does not appear to be consistent with a caudorostral spreading of alpha-synuclein aggregates. But if Lewy bodies are considered a mechanism to reduce the amount of soluble toxic alpha-synuclein oligomers in the cell, then the density of Lewy bodies in a given brain area may reflect its “defense” capability. In addition, if the caudorostral ascending process is tightly linked to the connectome of the involved structure, the locus coeruleus—with its lack of connections to the basal ganglia and, on the other hand, its strong projections to cortical areas—might drive the alpha-synuclein load of cortical areas many years longer than the SN might influence the alpha-synuclein load of the basal ganglia. This speculation is again testable in animal models and in post-mortem studies.</p></div><div class=section><a name=d48991e1676 class=n-a></a><h3 class=section-title>Search for Parkinson’s disease-modifying therapy delivers first results</h3><p class="" id=d48991e1681>The ultimate therapeutic challenge remains. Every person who knows a patient with PD asks why there is not a treatment that prevents the (at least) motor manifestation of PD. Already-diagnosed PD patients and their families dream of a treatment that can slow down or even partially reverse the progression of this devastating disorder with all its motor and non-motor symptoms and complications in the advanced stage. These dreams may be fulfilled in the not-too-distant future.</p><p class="" id=d48991e1684>Two therapeutic strategies are currently followed. The first is based on epidemiological findings and large clinical prospective trials reporting a correlation between a reduced occurrence or prevalence (or both) of PD and the consumption of compounds such as caffeine or nicotine (e.g., <a href="#ref-68">68</a>). <a href="#T4">Table 2</a> lists examples of these generic substances with a postulated disease-modifying potential for PD.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 2. Therapy with compounds of disease-modifying potential: generic substances.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d48991e1704 class=n-a></a><thead><a name=d48991e1706 class=n-a></a><tr><a name=d48991e1708 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1710 class=n-a></a>Compound</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1713 class=n-a></a>Indication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1716 class=n-a></a>Mode of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1719 class=n-a></a>Phase of<br class=br>development</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1724 class=n-a></a>Reference</th></tr></thead><tbody><a name=d48991e1729 class=n-a></a><tr><a name=d48991e1731 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d48991e1733 class=n-a></a>Caffeine<br class=br>(University of Montreal,<br class=br>Canada [C])</td><td align=left colspan=1 rowspan=1><a name=d48991e1740 class=n-a></a>Motor early<br class=br>Parkinson’s<br class=br>disease (PD)</td><td align=left colspan=1 rowspan=1><a name=d48991e1747 class=n-a></a>Adenosine-receptor<br class=br>antagonist</td><td align=left colspan=1 rowspan=1><a name=d48991e1752 class=n-a></a>Phase IIIb<br class=br>ongoing</td><td align=left colspan=1 rowspan=1><a name=d48991e1757 class=n-a></a>Wills <i>et al</i>. 2013<sup><a href="#ref-94">94</a></sup><br class=br>Postuma <i>et al</i>. 2012<sup><a href="#ref-95">95</a></sup></td></tr><tr><a name=d48991e1775 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d48991e1777 class=n-a></a>Inosine<br class=br>(Michael J. Fox Foundation<br class=br>[MJFF] [C])</td><td align=left colspan=1 rowspan=1><a name=d48991e1784 class=n-a></a>Motor early PD</td><td align=left colspan=1 rowspan=1><a name=d48991e1787 class=n-a></a>Precursor of urate,<br class=br>antioxidant</td><td align=left colspan=1 rowspan=1><a name=d48991e1792 class=n-a></a>Phase IIb<br class=br>ongoing</td><td align=left colspan=1 rowspan=1><a name=d48991e1797 class=n-a></a>Bhattacharyya <i>et al</i>. 2016<sup><a href="#ref-96">96</a></sup><br class=br>Ascherio <i>et al</i>. 2009<sup><a href="#ref-97">97</a></sup>]</td></tr><tr><a name=d48991e1816 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d48991e1818 class=n-a></a>Isradipine – STEADY-PDIII<br class=br>(NIH-NINDS, Novartis,<br class=br>University of Chicago [C])</td><td align=left colspan=1 rowspan=1><a name=d48991e1825 class=n-a></a>Motor early PD</td><td align=left colspan=1 rowspan=1><a name=d48991e1828 class=n-a></a>Dihydropyridine calcium<br class=br>channel blocker</td><td align=left colspan=1 rowspan=1><a name=d48991e1833 class=n-a></a>Phase IIIb<br class=br>ongoing</td><td align=left colspan=1 rowspan=1><a name=d48991e1838 class=n-a></a>Simuni <i>et al</i>. 2016<sup><a href="#ref-98">98</a></sup><br class=br>Simuni <i>et al</i>. 2013<sup><a href="#ref-99">99</a></sup></td></tr><tr><a name=d48991e1856 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d48991e1858 class=n-a></a>Nicotine - NIC-PD<br class=br>(German Parkinson Study<br class=br>Group, Parkinson Study<br class=br>Group USA; MJFF, IPF, NP,<br class=br>DPG, Novartis Germany [C])</td><td align=left colspan=1 rowspan=1><a name=d48991e1869 class=n-a></a>Motor <i>de novo</i> PD</td><td align=left colspan=1 rowspan=1><a name=d48991e1875 class=n-a></a>Cholinergic, modulation of<br class=br>α-synuclein aggregation?</td><td align=left colspan=1 rowspan=1><a name=d48991e1880 class=n-a></a>Phase IIIb<br class=br>completed</td><td align=left colspan=1 rowspan=1><a name=d48991e1885 class=n-a></a>Oertel <i>et al</i>. 2016<sup><a href="#ref-100">100</a></sup><br class=br>Quik <i>et al</i>. 2008<sup><a href="#ref-101">101</a></sup><br class=br>Hong <i>et al</i>. 2009<sup><a href="#ref-102">102</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d48991e1916 class=n-a></a><p id=d48991e1918> Modified from Oertel and Schulz<sup><a href="#ref-17">17</a></sup> (2016).</p></div></div></div><p class="" id=d48991e1928>The second approach relates to the groundbreaking genetic discoveries in PD. In fact, a dramatic shift in the strategy for developing a new PD therapy has taken place: pharmaceutical efforts now target alpha-synuclein protein synthesis, degradation (such as autophagia, lysosomal, or proteasomal degradation), protein aggregation, and propagation in the nervous system. Finally, 20 years after the discovery of <i>PARK1</i>, the academic and pharmaceutical industrial scientific community can offer the first candidates with a potential for a disease-modifying effect in PD.</p><p class="" id=d48991e1935>Three different principles of therapeutic action are addressed: (1) active or passive immunotherapy, (2) modulation of alpha-synuclein aggregation, and (3) enhancement of autophagy of alpha-synuclein (<a href="#T5">Table 3</a>).</p><div class="table-wrap panel clearfix"><a name=T5 class=n-a></a><div class=caption><h3>Table 3. Therapy with compounds targeting alpha-synuclein.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d48991e1952 class=n-a></a><thead><a name=d48991e1954 class=n-a></a><tr><a name=d48991e1956 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1958 class=n-a></a>Compound</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1961 class=n-a></a>Indication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1964 class=n-a></a>Mode of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1967 class=n-a></a>Phase of development</th><th align=left colspan=1 rowspan=1 valign=top><a name=d48991e1970 class=n-a></a>Reference</th></tr></thead><tbody><a name=d48991e1975 class=n-a></a><tr><a name=d48991e1977 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1979 class=n-a></a><i>Immunotherapy (IT)</i></td><td align=left colspan=1 rowspan=1><a name=d48991e1983 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e1985 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e1987 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e1989 class=n-a></a></td></tr><tr><a name=d48991e1992 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1994 class=n-a></a>Active immunization<br class=br>(Affiris [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e1999 class=n-a></a>Motor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2002 class=n-a></a>IT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2005 class=n-a></a>Phase II ongoing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2008 class=n-a></a>Schneeberger <i>et al</i>. 2016<sup><a href="#ref-103">103</a></sup><br class=br>Manoutcharian <i>et al</i>. 2016<sup><a href="#ref-104">104</a></sup></td></tr><tr><a name=d48991e2026 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2028 class=n-a></a>Passive immunization<br class=br>BIIB054<br class=br>(Biogen [C])<br class=br>PRX002<br class=br>(Parthena/Roche [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2039 class=n-a></a>Motor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2042 class=n-a></a>IT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2045 class=n-a></a>Phase II in preparation<br class=br>phase II in preparation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2050 class=n-a></a>Weihofen <i>et al</i>. 2016<sup><a href="#ref-105">105</a></sup><br class=br>Bergström <i>et al</i>. 2016<sup><a href="#ref-106">106</a></sup><br class=br>Kalia <i>et al</i>. 2015<sup><a href="#ref-6">6</a></sup><br class=br>Games <i>et al</i>. 2014<sup><a href="#ref-107">107</a></sup><br class=br>Spencer <i>et al</i>. 2016<sup><a href="#ref-69">69</a></sup></td></tr><tr><a name=d48991e2094 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2096 class=n-a></a><i>Alpha-synuclein</i><br class=br><i>aggregation modulators</i><br class=br><i>(aSAMs)</i></td><td align=left colspan=1 rowspan=1><a name=d48991e2106 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2108 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2110 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2112 class=n-a></a></td></tr><tr><a name=d48991e2115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2117 class=n-a></a>NPT200-11<br class=br>(UCB/Neuropore [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2122 class=n-a></a>Motor?<br class=br>likely in <i>de novo</i><br class=br>Parkinson’s<br class=br>disease (PD)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2133 class=n-a></a>aSAM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2136 class=n-a></a>Phase I in planning</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2139 class=n-a></a>Koike <i>et al</i>. 2014<sup><a href="#ref-74">74</a></sup><br class=br>Szoke <i>et al</i>. 2014<sup><a href="#ref-75">75</a></sup></td></tr><tr><a name=d48991e2158 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2160 class=n-a></a><i>NPT100_18a</i><br class=br>(Neuropore [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2166 class=n-a></a>Not applicable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2169 class=n-a></a>aSAM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2172 class=n-a></a>Preclinical testing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2175 class=n-a></a>Wrasidlo <i>et al</i>. 2016<sup><a href="#ref-75">75</a></sup></td></tr><tr><a name=d48991e2185 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2187 class=n-a></a>ANLE 138b<br class=br>(MODAG [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2192 class=n-a></a>Motor?<br class=br>likely in <i>de novo</i><br class=br>PD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2201 class=n-a></a>aSAM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2204 class=n-a></a>Phase I in planning</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2207 class=n-a></a>Deeg <i>et al</i>. 2015<sup><a href="#ref-73">73</a></sup><br class=br>Levin <i>et al</i>. 2014<sup><a href="#ref-72">72</a></sup><br class=br>Wagner <i>et al</i>. 2013<sup><a href="#ref-71">71</a></sup></td></tr><tr><a name=d48991e2234 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2236 class=n-a></a><i>a-synuclein autophagia</i><br class=br><i>enhancer (aSAE)</i></td><td align=left colspan=1 rowspan=1><a name=d48991e2243 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2245 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2247 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d48991e2249 class=n-a></a></td></tr><tr><a name=d48991e2252 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2254 class=n-a></a>Nilotinib<br class=br><i>Tasigna off-label use</i><br class=br>(Georgetown University,<br class=br>Washington, DC, USA [C])</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2264 class=n-a></a>Motor<br class=br>non-motor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2269 class=n-a></a>“Tyrosine kinase<br class=br>inhibitor”<br class=br>aSAE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2276 class=n-a></a>Investigator initiated trial<br class=br>– open-label small pilot study<br class=br>randomized controlled trial in<br class=br>planning<br class=br>(MJFF-USA, Cure PD Trust,<br class=br>UK)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d48991e2289 class=n-a></a>Pagan <i>et al</i>. 2016<sup><a href="#ref-78">78</a></sup><br class=br>Hebron <i>et al</i>. 2014<sup><a href="#ref-80">80</a></sup><br class=br>Hebron <i>et al</i>. 2013<sup><a href="#ref-81">81</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d48991e2320 class=n-a></a><p id=d48991e2322> Modified from Oertel and Schulz<sup><a href="#ref-16">16</a></sup> (2016).</p></div></div></div><p class="" id=d48991e2332>1) The first approach mimics a strategy that has been followed in Alzheimer’s disease for the last decade: active and passive immunizations are being developed as therapeutic approaches. This immunotherapeutic strategy relies on the assumption that (a) alpha-synuclein is accessible in the extracellular space (trans-synaptic spreading), (b) antibodies against alpha-synuclein reach the brain in sufficient quantity, and (c) they trap alpha-synuclein aggregates when these are released (“spread”) into the extracellular synaptic space. Today, active and passive immunization trials are under way in phases I and II. These treatments have passed the safety level testing, and the first data on phase II trials are awaited in 2017 to 2019. One limitation of active and passive immunotherapy, the low amount of antibodies passing the blood-brain barrier, may be overcome by coupling antibodies to the peptide penetratin, as has recently been reported in a mouse PD model<sup><a href="#ref-69">69</a></sup>.</p><p class="" id=d48991e2339>2) Modulating the aggregation of alpha-synuclein aims to block or reduce the aggregation of alpha-synuclein monomers to oligomers or later on to fibrils. Two drugs are close to or under very early development. The first compound is called ANLE138b, and the few articles published demonstrate that this drug is able to reduce the aggregation of alpha-synuclein. In addition, in a mouse model with an A30P alpha-synuclein mutation, the compound extends survival<sup><a href="#ref-70">70</a>–<a href="#ref-72">72</a></sup>. The second drug is called NPT200-11, and only abstracts on its efficacy in preclinical testing are in the public domain<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>. This compound again reduces aggregation of alpha-synuclein at least <i>in vitro</i> and according to public information should have reached the very first safety testing in humans. A third compound NPT100-18a has been reported to displace alpha-synuclein from membranes, but is still in the phase of preclinical testing<sup><a href="#ref-75">75</a></sup>. The advantage of these small molecules is that, in variance to antibodies employed in immunotherapeutic attempts, they readily pass the blood-brain barrier.</p><p class="" id=d48991e2363>3) Other newly developed compounds promise to enhance autophagy of alpha-synuclein. They are still in preclinical testing, although screening of libraries of registered compounds may well reveal further potential members of this group<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d48991e2370>In 2015, a report from a research group at Georgetown University (Washington, DC, USA) may unexpectedly reduce the time to an available registered and reimbursed disease-modifying therapy of PD<sup><a href="#ref-77">77</a></sup>. The neurologists treated 12 patients with PD in advanced stages—including PD patients with cognitive impairment—with the compound nilotinib, a tyrosine kinase inhibitor approved as a therapy for chronic myeloid leukemia. Patients with PD were treated in a safety study with an open-label design (150 or 300 mg daily), and after 6 months of therapy, a clinical improvement was reported. In articles published between 2012 and 2014, nilotinib had been shown to reduce alpha-synuclein levels in protein aggregation models of PD in rodents and to prevent the loss of dopaminergic neurons in a transgenic PD mouse model. Its mode of action is to increase autophagy<sup><a href="#ref-78">78</a>,<a href="#ref-79">79</a></sup>. In the meantime, the Michael J. Fox Foundation (MJFF), together with Cure Parkinson’s disease trust in the UK, picked up this finding, which initially was looked at very skeptically, and decided to test nilotinib in a double-blind controlled study in patients with PD.</p><p class="" id=d48991e2385>In summary, the field has steadily shifted from developments on symptomatic therapy to preventive therapy, with at least five different options (active immunization, passive immunization, two small molecules that function as alpha-synuclein aggregation modulators, and most recently an autophagy enhancer with a known adverse profile, which is already registered in the field of oncology). Thus, for the very first time, the possibility of a disease-modifying therapy appears to be testable in PD.</p></div><div class=section><a name=d48991e2389 class=n-a></a><h3 class=section-title>Search for primary endpoints reflecting the progression of Parkinson’s disease in the prodromal stages</h3><p class="" id=d48991e2394>Taking together the discoveries on the genetic background of PD and the Braak staging hypothesis, new avenues for drug development and clinical testing have opened up. For clinical testing—at least in the next few years—potential disease-modifying compounds are and will be tested in the early stage of motor PD; that is, very early <i>de novo</i> PD patients, who never received a symptomatic therapy will be recruited and should present with a unilateral asymmetric very mild motor symptomatology.</p><p class="" id=d48991e2400>However, for “true” neuroprevention (that is, the prevention or delay of the conversion of a prodromal stage to the motor stage of PD), parameters and biomarkers which reflect the progression of the alpha-synucleinopathy in the prodromal stage have to be discovered. In addition, such a parameter must be responsive to therapy, even in the prodromal stage, in order to qualify as a primary endpoint for pivotal registration trials. At present, such a parameter has not been identified. Respective research ranges from studies on biomarkers in the cerebrospinal fluid, peripheral blood, saliva, and sweat and in biopsies of the colonic enteric nervous system, the salivary gland, or the skin<sup><a href="#ref-80">80</a>–<a href="#ref-83">83</a></sup>. Major efforts are placed into different imaging techniques with sophisticated magnetic resonance methods, nuclear medical ligands for the dopamine transporter single-positron emission computed tomography (SPECT) or fluoro-desoxyglucose positron emission tomography<sup><a href="#ref-84">84</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d48991e2418>Conclusions</h2><p class="" id=d48991e2421>Neurologists have to accept that the majority of patients with PD, even at the very early stage of neurological diagnosis, actually present a late-stage phenotype of an alpha-synucleinopathy. Thus, PD has started at least 20 years before it manifests in the clinic with its motor symptoms. Neurologists will likely have to shift their clinical and diagnostic focus away from the dopaminergic system to symptoms related to different parts of the nervous system, such as the enteric system<sup><a href="#ref-62">62</a></sup>, the brainstem with its autonomic control areas, the locus coeruleus<sup><a href="#ref-57">57</a></sup>, or even the skin. If the dream of a disease-modifying therapy is to come true, neuroscience, drug development, and physician scientists face at least two challenges. First, drug development will target the aggregation and propagation of alpha-synuclein and of related mechanisms as well as mitochondrial dysfunction; second, a major effort has to be made to enhance the diagnostic methodology in order to identify a primary endpoint for clinical neuroprotective trials, not only in early motor PD but also in the prodromal stages of PD<sup><a href="#ref-82">82</a>–<a href="#ref-84">84</a></sup>. It has never been so exciting as today to work in the field of PD, and we should share this belief with the patients we diagnose, treat, and care for.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d48991e1 class=n-a></a><h2 class=main-title id=d49350>Competing interests</h2><p class=metadata-entry><a name=d48991e83 class=n-a></a><p id=d48991e84> The author declares that he has no competing interests.</p></p></div><div class=back-section><a name=d48991e1 class=n-a></a><h2 class=main-title id=d49352>Grant information</h2><p>WH Oertel is Hertie Senior Research Professor supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany.</p></div><div class=back-section><a name=d48991e2443 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d49691>References</h2><div class="section ref-list"><a name=d48991e2443 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d48991e2450 class=n-a></a>Hughes AJ, Daniel SE, Ben-Shlomo Y, <i> et al.</i>: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. <i>Brain.</i> 2002; <b>125</b>(Pt 4): 861–70. <a target=xrefwindow id=d48991e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/11912118">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2464 href="http://dx.doi.org/10.1093/brain/awf080">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d48991e2473 class=n-a></a>Lewy FH: Paralysis agitans. I. Pathologische Anatomie. In: <i>Handbuch der Neurologie</i> (Lewandoski M, Hrsg), Springer Berlin. <b>III</b>: 920–933. </span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d48991e2488 class=n-a></a>Spillantini MG, Schmidt ML, Lee VM, <i> et al.</i>: Alpha-synuclein in Lewy bodies. <i>Nature.</i> 1997; <b>388</b>(6645): 839–40. <a target=xrefwindow id=d48991e2499 href="http://www.ncbi.nlm.nih.gov/pubmed/9278044">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2502 href="http://dx.doi.org/10.1038/42166">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d48991e2511 class=n-a></a>Tretiakoff C: Contribution a l'etude l'anatomie pathologique du locus Niger de soemmering: avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Jouve Paris. 1919. <a target=xrefwindow id=d48991e2513 href="https://books.google.co.in/books/about/Contribution_a_l_etude_l_anatomie_pathol.html?id=ySC0mgEACAAJ&amp;redir_esc=y">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d48991e2522 class=n-a></a>Birkmayer W, Hornykiewicz O: [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. <i>Wien Klin Wochenschr.</i> 1961; <b>73</b>: 787–8. <a target=xrefwindow id=d48991e2530 href="http://www.ncbi.nlm.nih.gov/pubmed/13869404">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d48991e2540 class=n-a></a>Kalia LV, Kalia SK, Lang AE: Disease-modifying strategies for Parkinson's disease. <i>Mov Disord.</i> 2015; <b>30</b>(11): 1442–50. <a target=xrefwindow id=d48991e2548 href="http://www.ncbi.nlm.nih.gov/pubmed/26208210">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2551 href="http://dx.doi.org/10.1002/mds.26354">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d48991e2560 class=n-a></a>Polymeropoulos MH, Lavedan C, Leroy E, <i> et al.</i>: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. <i>Science.</i> 1997; <b>276</b>(5321): 2045–7. <a target=xrefwindow id=d48991e2571 href="http://www.ncbi.nlm.nih.gov/pubmed/9197268">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2574 href="http://dx.doi.org/10.1126/science.276.5321.2045">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d48991e2583 class=n-a></a>Braak H, Del Tredici K, Rüb U, <i> et al.</i>: Staging of brain pathology related to sporadic Parkinson's disease. <i>Neurobiol Aging.</i> 2003; <b>24</b>(2): 197–211. <a target=xrefwindow id=d48991e2594 href="http://www.ncbi.nlm.nih.gov/pubmed/12498954">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2597 href="http://dx.doi.org/10.1016/S0197-4580(02)00065-9">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d48991e2606 class=n-a></a>Hawkes CH, Del Tredici K, Braak H: Parkinson's disease: a dual-hit hypothesis. <i>Neuropathol Appl Neurobiol.</i> 2007; <b>33</b>(6): 599–614. <a target=xrefwindow id=d48991e2614 href="http://www.ncbi.nlm.nih.gov/pubmed/17961138">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2617 href="http://dx.doi.org/10.1111/j.1365-2990.2007.00874.x">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726560055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2626 class=n-a></a>Martínez-Fernández R, Schmitt E, Martinez-Martin P, <i> et al.</i>: The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. <i>Mov Disord.</i> 2016; <b>31</b>(8): 1080–94. <a target=xrefwindow id=d48991e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/27431515">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2640 href="http://dx.doi.org/10.1002/mds.26731">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726560055">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d48991e2653 class=n-a></a>Seppi K, Weintraub D, Coelho M, <i> et al.</i>: The <i>Movement</i> Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Mov Disord.</i> 2011; <b>26 Suppl 3</b>: S42–80. <a target=xrefwindow id=d48991e2667 href="http://www.ncbi.nlm.nih.gov/pubmed/22021174">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2671 href="http://dx.doi.org/10.1002/mds.23884">Publisher Full Text </a> | <a target=xrefwindow id=d48991e2674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4020145">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1050531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2684 class=n-a></a>Deuschl G, Schade-Brittinger C, Krack P, <i> et al.</i>: A randomized trial of deep-brain stimulation for Parkinson's disease. <i>N Engl J Med.</i> 2006; <b>355</b>(9): 896–908. <a target=xrefwindow id=d48991e2695 href="http://www.ncbi.nlm.nih.gov/pubmed/16943402">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2698 href="http://dx.doi.org/10.1056/NEJMoa060281">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1050531">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718003008"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2711 class=n-a></a>Schuepbach WM, Rau J, Knudsen K, <i> et al.</i>: Neurostimulation for Parkinson's disease with early motor complications. <i>N Engl J Med.</i> 2013; <b>368</b>(7): 610–22. <a target=xrefwindow id=d48991e2722 href="http://www.ncbi.nlm.nih.gov/pubmed/23406026">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2725 href="http://dx.doi.org/10.1056/NEJMoa1205158">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718003008">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d48991e2738 class=n-a></a>de Vries NM, Sturkenboom IH, Bloem BR: Physiotherapy and Occupational Therapy and Mild to Moderate Parkinson Disease. <i>JAMA Neurol.</i> 2016; <b>73</b>(7): 893–4. <a target=xrefwindow id=d48991e2746 href="http://www.ncbi.nlm.nih.gov/pubmed/27243578">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2749 href="http://dx.doi.org/10.1001/jamaneurol.2016.1277">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725720979"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2758 class=n-a></a>Bloem BR, de Vries NM, Ebersbach G: Nonpharmacological treatments for patients with Parkinson's disease. <i>Mov Disord.</i> 2015; <b>30</b>(11): 1504–20. <a target=xrefwindow id=d48991e2766 href="http://www.ncbi.nlm.nih.gov/pubmed/26274930">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2769 href="http://dx.doi.org/10.1002/mds.26363">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725720979">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d48991e2782 class=n-a></a>LaHue SC, Comella CL, Tanner CM: The best medicine? The influence of physical activity and inactivity on Parkinson's disease. <i>Mov Disord.</i> 2016; <b>31</b>(10): 1444–54. <a target=xrefwindow id=d48991e2790 href="http://www.ncbi.nlm.nih.gov/pubmed/27477046">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2793 href="http://dx.doi.org/10.1002/mds.26728">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d48991e2802 class=n-a></a>Oertel W, Schulz JB: Current and experimental treatments of Parkinson disease: A guide for neuroscientists. <i>J Neurochem.</i> 2016; <b>139 Suppl 1</b>: 325–37. <a target=xrefwindow id=d48991e2810 href="http://www.ncbi.nlm.nih.gov/pubmed/27577098">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2813 href="http://dx.doi.org/10.1111/jnc.13750">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718215458"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2823 class=n-a></a>Olanow CW, Kieburtz K, Odin P, <i> et al.</i>: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurol.</i> 2014; <b>13</b>(2): 141–9. <a target=xrefwindow id=d48991e2834 href="http://www.ncbi.nlm.nih.gov/pubmed/24361112">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2837 href="http://dx.doi.org/10.1016/S1474-4422(13)70293-X">Publisher Full Text </a> | <a target=xrefwindow id=d48991e2841 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4643396">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718215458">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717995409"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e2854 class=n-a></a>Hauser RA, Hsu A, Kell S, <i> et al.</i>: Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. <i>Lancet Neurol.</i> 2013; <b>12</b>(4): 346–56. <a target=xrefwindow id=d48991e2865 href="http://www.ncbi.nlm.nih.gov/pubmed/23485610">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2868 href="http://dx.doi.org/10.1016/S1474-4422(13)70025-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717995409">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d48991e2881 class=n-a></a>Pahwa R, Lyons KE, Hauser RA, <i> et al.</i>: Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism Relat Disord.</i> 2014; <b>20</b>(2): 142–8. <a target=xrefwindow id=d48991e2892 href="http://www.ncbi.nlm.nih.gov/pubmed/24055014">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2895 href="http://dx.doi.org/10.1016/j.parkreldis.2013.08.017">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d48991e2904 class=n-a></a>Stocchi F, Hsu A, Khanna S, <i> et al.</i>: Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. <i>Parkinsonism Relat Disord.</i> 2014; <b>20</b>(12): 1335–40. <a target=xrefwindow id=d48991e2915 href="http://www.ncbi.nlm.nih.gov/pubmed/25306200">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2918 href="http://dx.doi.org/10.1016/j.parkreldis.2014.08.004">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d48991e2927 class=n-a></a>Waters CH, Nausieda P, Dzyak L, <i> et al.</i>: Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial. <i>CNS Drugs.</i> 2015; <b>29</b>(4): 341–50. <a target=xrefwindow id=d48991e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/25895021">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2941 href="http://dx.doi.org/10.1007/s40263-015-0242-2">Publisher Full Text </a> | <a target=xrefwindow id=d48991e2945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4555339">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d48991e2954 class=n-a></a>Hsu A, Yao HM, Gupta S, <i> et al.</i>: Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(<sup>®</sup>)), sustained-release carbidopa-levodopa (Sinemet(<sup>®</sup>) CR), and carbidopa-levodopa-entacapone (Stalevo(<sup>®</sup>)). <i>J Clin Pharmacol.</i> 2015; <b>55</b>(9): 995–1003. <a target=xrefwindow id=d48991e2975 href="http://www.ncbi.nlm.nih.gov/pubmed/25855267">PubMed Abstract </a> | <a target=xrefwindow id=d48991e2978 href="http://dx.doi.org/10.1002/jcph.514">Publisher Full Text </a> | <a target=xrefwindow id=d48991e2981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5032972">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d48991e2991 class=n-a></a>Mao ZL, Modi NB: Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease. <i>J Clin Pharmacol.</i> 2016; <b>56</b>(8): 974–82. <a target=xrefwindow id=d48991e2999 href="http://www.ncbi.nlm.nih.gov/pubmed/26632091">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3002 href="http://dx.doi.org/10.1002/jcph.683">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5066683">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d48991e3014 class=n-a></a>Yao HM, Hsu A, Gupta S, <i> et al.</i>: Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers. <i>Clin Neuropharmacol.</i> 2016; <b>39</b>(1): 10–7. <a target=xrefwindow id=d48991e3025 href="http://www.ncbi.nlm.nih.gov/pubmed/26626430">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3028 href="http://dx.doi.org/10.1097/WNF.0000000000000126">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3032 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4714633">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727345485"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3041 class=n-a></a>Nausieda PA, Hsu A, Elmer L, <i> et al.</i>: Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials. <i>J Parkinsons Dis.</i> 2015; <b>5</b>(4): 837–45. <a target=xrefwindow id=d48991e3052 href="http://www.ncbi.nlm.nih.gov/pubmed/26444090">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3055 href="http://dx.doi.org/10.3233/JPD-150622">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927929">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727345485">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d48991e3072 class=n-a></a>Stocchi F, Borgohain R, Onofrj M, <i> et al.</i>: A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. <i>Mov Disord.</i> 2012; <b>27</b>(1): 106–12. <a target=xrefwindow id=d48991e3083 href="http://www.ncbi.nlm.nih.gov/pubmed/21913224">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3086 href="http://dx.doi.org/10.1002/mds.23954">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d48991e3095 class=n-a></a>Schapira AH, Stocchi F, Borgohain R, <i> et al.</i>: Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. <i>Eur J Neurol.</i> 2013; <b>20</b>(2): 271–80. <a target=xrefwindow id=d48991e3106 href="http://www.ncbi.nlm.nih.gov/pubmed/22967035">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3109 href="http://dx.doi.org/10.1111/j.1468-1331.2012.03840.x">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d48991e3118 class=n-a></a>Borgohain R, Szasz J, Stanzione P, <i> et al.</i>: Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. <i>Mov Disord.</i> 2014; <b>29</b>(2): 229–37. <a target=xrefwindow id=d48991e3129 href="http://www.ncbi.nlm.nih.gov/pubmed/24323641">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3132 href="http://dx.doi.org/10.1002/mds.25751">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3136 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4285943">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d48991e3146 class=n-a></a>Borgohain R, Szasz J, Stanzione P, <i> et al.</i>: Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. <i>Mov Disord.</i> 2014; <b>29</b>(10): 1273–80. <a target=xrefwindow id=d48991e3157 href="http://www.ncbi.nlm.nih.gov/pubmed/25044402">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3160 href="http://dx.doi.org/10.1002/mds.25961">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726170973"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3169 class=n-a></a>Cattaneo C, Sardina M, Bonizzoni E: Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: <i>Post hoc</i> Analyses of Studies 016 and SETTLE. <i>J Parkinsons Dis.</i> 2016; <b>6</b>(1): 165–73. <a target=xrefwindow id=d48991e3180 href="http://www.ncbi.nlm.nih.gov/pubmed/26889632">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3183 href="http://dx.doi.org/10.3233/JPD-150700">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3187 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927927">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726170973">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727345491"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3200 class=n-a></a>Stocchi F, Torti M: Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. <i>Drug Des Devel Ther.</i> 2016; <b>10</b>: 609–18. <a target=xrefwindow id=d48991e3208 href="http://www.ncbi.nlm.nih.gov/pubmed/26917951">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3211 href="http://dx.doi.org/10.2147/DDDT.S77749">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3214 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4751980">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727345491">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726054684"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3227 class=n-a></a>Ferreira JJ, Lees A, Rocha JF, <i> et al.</i>: Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurol.</i> 2015; <b>15</b>(2): 154–165, pii: S1474-4422(15)00336-1. <a target=xrefwindow id=d48991e3238 href="http://www.ncbi.nlm.nih.gov/pubmed/26725544">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3241 href="http://dx.doi.org/10.1016/S1474-4422(15)00336-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726054684">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d48991e3254 class=n-a></a>Fabbri M, Rosa MM, Ferreira JJ: Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. <i>Neurodegener Dis Manag.</i> 2016; <b>6</b>(5): 349–62. <a target=xrefwindow id=d48991e3262 href="http://www.ncbi.nlm.nih.gov/pubmed/27599671">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3265 href="http://dx.doi.org/10.2217/nmt-2016-0022">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d48991e3274 class=n-a></a>Rocha JF, Ferreira JJ, Falcão A, <i> et al.</i>: Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. <i>Clin Pharmacol Drug Dev.</i> 2016; <b>5</b>(3): 232–240. <a target=xrefwindow id=d48991e3285 href="http://www.ncbi.nlm.nih.gov/pubmed/27163503">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3288 href="http://dx.doi.org/10.1002/cpdd.217">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725349331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3298 class=n-a></a>Pahwa R, Tanner CM, Hauser RA, <i> et al.</i>: Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). <i>Mov Disord.</i> 2015; <b>30</b>(6): 788–95. <a target=xrefwindow id=d48991e3309 href="http://www.ncbi.nlm.nih.gov/pubmed/25650051">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3312 href="http://dx.doi.org/10.1002/mds.26159">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3316 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5024015">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725349331">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d48991e3329 class=n-a></a>Pahwa R, Tanner CM, Hauser RA, <i> et al.</i>: Results of a phase 3 efficacy and safety study of ADS-5102 (amantadine HCl) extended-release capsules in Parkinson’s disease patients with Levodopa-induced dyskinesia (EASE LID 3). International Movement Disorder Congress, Berlin, Late breaking abstract 7, 2016. </span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d48991e3341 class=n-a></a>Mizuno Y, Hasegawa K, Kondo T, <i> et al.</i>: Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. <i>Mov Disord.</i> 2010; <b>25</b>(10): 1437–43. <a target=xrefwindow id=d48991e3352 href="http://www.ncbi.nlm.nih.gov/pubmed/20629136">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3355 href="http://dx.doi.org/10.1002/mds.23107">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d48991e3364 class=n-a></a>Mizuno Y, Kondo T, Japanese Istradefylline Study Group: Adenosine A<sub>2A</sub> receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. <i>Mov Disord.</i> 2013; <b>28</b>(8): 1138–41. <a target=xrefwindow id=d48991e3375 href="http://www.ncbi.nlm.nih.gov/pubmed/23483627">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3378 href="http://dx.doi.org/10.1002/mds.25418">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3842830">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d48991e3391 class=n-a></a>Kondo T, Mizuno Y, Japanese Istradefylline Study Group: A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. <i>Clin Neuropharmacol.</i> 2015; <b>38</b>(2): 41–6. <a target=xrefwindow id=d48991e3399 href="http://www.ncbi.nlm.nih.gov/pubmed/25768849">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3402 href="http://dx.doi.org/10.1097/WNF.0000000000000073">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d48991e3411 class=n-a></a>Factor S, Mark MH, Watts R, <i> et al.</i>: A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. <i>Parkinsonism Relat Disord.</i> 2010; <b>16</b>(6): 423–6. <a target=xrefwindow id=d48991e3422 href="http://www.ncbi.nlm.nih.gov/pubmed/20338800">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3425 href="http://dx.doi.org/10.1016/j.parkreldis.2010.02.014">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d48991e3435 class=n-a></a>Pourcher E, Fernandez HH, Stacy M, <i> et al.</i>: Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. <i>Parkinsonism Relat Disord.</i> 2012; <b>18</b>(2): 178–84. <a target=xrefwindow id=d48991e3446 href="http://www.ncbi.nlm.nih.gov/pubmed/22000279">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3449 href="http://dx.doi.org/10.1016/j.parkreldis.2011.09.023">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d48991e3458 class=n-a></a>Vorovenci RJ, Antonini A: The efficacy of oral adenosine A<sub>2A</sub> antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. <i>Expert Rev Neurother.</i> 2015; <b>15</b>(12): 1383–90. <a target=xrefwindow id=d48991e3469 href="http://www.ncbi.nlm.nih.gov/pubmed/26630457">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3472 href="http://dx.doi.org/10.1586/14737175.2015.1113131">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d48991e3481 class=n-a></a>Pinna A: Adenosine A<sub>2A</sub> receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. <i>CNS Drugs.</i> 2014; <b>28</b>(5): 455–74. <a target=xrefwindow id=d48991e3492 href="http://www.ncbi.nlm.nih.gov/pubmed/24687255">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3495 href="http://dx.doi.org/10.1007/s40263-014-0161-7">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d48991e3504 class=n-a></a>Stocchi F, Rascol O, Destee A, <i> et al.</i>: AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Mov Disord.</i> 2013; <b>28</b>(13): 1838–46. <a target=xrefwindow id=d48991e3515 href="http://www.ncbi.nlm.nih.gov/pubmed/23853029">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3518 href="http://dx.doi.org/10.1002/mds.25561">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d48991e3527 class=n-a></a>Petrov D, Pedros I, de Lemos ML, <i> et al.</i>: Mavoglurant as a treatment for Parkinson's disease. <i>Expert Opin Investig Drugs.</i> 2014; <b>23</b>(8): 1165–79. <a target=xrefwindow id=d48991e3538 href="http://www.ncbi.nlm.nih.gov/pubmed/24960254">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3541 href="http://dx.doi.org/10.1517/13543784.2014.931370">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d48991e3550 class=n-a></a>Rascol O, Fox S, Gasparini F, <i> et al.</i>: Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. <i>Parkinsonism Relat Disord.</i> 2014; <b>20</b>(9): 947–56. <a target=xrefwindow id=d48991e3561 href="http://www.ncbi.nlm.nih.gov/pubmed/24951359">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3564 href="http://dx.doi.org/10.1016/j.parkreldis.2014.05.003">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726375516"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3574 class=n-a></a>Trenkwalder C, Stocchi F, Poewe W, <i> et al.</i>: Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies. <i>Mov Disord.</i> 2016; <b>31</b>(7): 1054–8. <a target=xrefwindow id=d48991e3585 href="http://www.ncbi.nlm.nih.gov/pubmed/27214258">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3588 href="http://dx.doi.org/10.1002/mds.26585">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726375516">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d48991e3601 class=n-a></a>Trenkwalder C, Berg D, Rascol O, <i> et al.</i>: A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Mov Disord.</i> 2016; <b>31</b>(7): 1049–54. <a target=xrefwindow id=d48991e3612 href="http://www.ncbi.nlm.nih.gov/pubmed/26990766">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3615 href="http://dx.doi.org/10.1002/mds.26569">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d48991e3624 class=n-a></a>Barbe MT, Maarouf M, Alesch F, <i> et al.</i>: Multiple source current steering--a novel deep brain stimulation concept for customized programming in a Parkinson's disease patient. <i>Parkinsonism Relat Disord.</i> 2014; <b>20</b>(4): 471–3. <a target=xrefwindow id=d48991e3635 href="http://www.ncbi.nlm.nih.gov/pubmed/24041939">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3638 href="http://dx.doi.org/10.1016/j.parkreldis.2013.07.021">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726501513"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3647 class=n-a></a>Timmermann L, Jain R, Chen L, <i> et al.</i>: 134 VANTAGE Trial: Three-Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation With a New Multiple-Source, Constant-Current Rechargeable System in Parkinson Disease. <i>Neurosurgery.</i> 2016; <b>63</b>(Suppl 1): 155. <a target=xrefwindow id=d48991e3658 href="http://www.ncbi.nlm.nih.gov/pubmed/27399413">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3661 href="http://dx.doi.org/10.1227/01.neu.0000489704.68466.0a">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726501513">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726407271"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3674 class=n-a></a>McIntyre CC, Anderson RW: Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation. <i>J Neurochem.</i> 2016; <b>139</b>(Suppl 1): 338–45. <a target=xrefwindow id=d48991e3682 href="http://www.ncbi.nlm.nih.gov/pubmed/27273305">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3685 href="http://dx.doi.org/10.1111/jnc.13649">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726407271">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718164088"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3698 class=n-a></a>Cummings J, Isaacson S, Mills R, <i> et al.</i>: Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. <i>Lancet.</i> 2014; <b>383</b>(9916): 533–40. <a target=xrefwindow id=d48991e3709 href="http://www.ncbi.nlm.nih.gov/pubmed/24183563">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3712 href="http://dx.doi.org/10.1016/S0140-6736(13)62106-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718164088">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725872859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3726 class=n-a></a>Trenkwalder C, Chaudhuri KR, Martinez-Martin P, <i> et al.</i>: Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurol.</i> 2015; <b>14</b>(12): 1161–70. <a target=xrefwindow id=d48991e3737 href="http://www.ncbi.nlm.nih.gov/pubmed/26494524">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3740 href="http://dx.doi.org/10.1016/S1474-4422(15)00243-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725872859">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d48991e3753 class=n-a></a>Mathias CJ, Senard JM, Braune S, <i> et al.</i>: L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. <i>Clin Auton Res.</i> 2001; <b>11</b>(4): 235–42. <a target=xrefwindow id=d48991e3764 href="http://www.ncbi.nlm.nih.gov/pubmed/11710796">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3767 href="http://dx.doi.org/10.1007/BF02298955">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d48991e3776 class=n-a></a>Hauser RA, Hewitt LA, Isaacson S: Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). <i>J Parkinsons Dis.</i> 2014; <b>4</b>(1): 57–65. <a target=xrefwindow id=d48991e3784 href="http://www.ncbi.nlm.nih.gov/pubmed/24326693">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3787 href="http://dx.doi.org/10.3233/JPD-130259">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720592698"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3796 class=n-a></a>Espay AJ, LeWitt PA, Kaufmann H: Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. <i>Mov Disord.</i> 2014; <b>29</b>(14): 1710–9. <a target=xrefwindow id=d48991e3804 href="http://www.ncbi.nlm.nih.gov/pubmed/25297066">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3807 href="http://dx.doi.org/10.1002/mds.26048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720592698">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725815045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3820 class=n-a></a>Dafsari HS, Reddy P, Herchenbach C, <i> et al.</i>: Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimul.</i> 2016; <b>9</b>(1): 78–85. <a target=xrefwindow id=d48991e3831 href="http://www.ncbi.nlm.nih.gov/pubmed/26385442">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3834 href="http://dx.doi.org/10.1016/j.brs.2015.08.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725815045">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d48991e3847 class=n-a></a>Hernandez DG, Reed X, Singleton AB: Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. <i>J Neurochem.</i> 2016; <b>139</b>(Suppl 1): 59–74. <a target=xrefwindow id=d48991e3855 href="http://www.ncbi.nlm.nih.gov/pubmed/27090875">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3858 href="http://dx.doi.org/10.1111/jnc.13593">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5155439">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d48991e3871 class=n-a></a>Hoglinger GU, Alvarez-Fischer D, Arias-Carrion O, <i> et al.</i>: A new dopaminergic nigro-olfactory projection. <i>Acta Neuropathol.</i> 2015; <b>130</b>(3): 333–48. <a target=xrefwindow id=d48991e3882 href="http://www.ncbi.nlm.nih.gov/pubmed/26072303">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3885 href="http://dx.doi.org/10.1007/s00401-015-1451-y">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d48991e3893 class=n-a></a>Kordower JH, Chu Y, Hauser RA, <i> et al.</i>: Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nat Med.</i> 2008; <b>14</b>(5): 504–6. <a target=xrefwindow id=d48991e3904 href="http://www.ncbi.nlm.nih.gov/pubmed/18391962">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3907 href="http://dx.doi.org/10.1038/nm1747">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727046232"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3916 class=n-a></a>Sampson TR, Debelius JW, Thron T, <i> et al.</i>: Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. <i>Cell.</i> 2016; <b>167</b>(6): 1469–1480.e12. <a target=xrefwindow id=d48991e3927 href="http://www.ncbi.nlm.nih.gov/pubmed/27912057">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3930 href="http://dx.doi.org/10.1016/j.cell.2016.11.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727046232">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d48991e3943 class=n-a></a>Schenck CH, Montplaisir JY, Frauscher B, <i> et al.</i>: Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. <i>Sleep Med.</i> 2013; <b>14</b>(8): 795–806. <a target=xrefwindow id=d48991e3954 href="http://www.ncbi.nlm.nih.gov/pubmed/23886593">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3957 href="http://dx.doi.org/10.1016/j.sleep.2013.02.016">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718294332"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3966 class=n-a></a>Iranzo A, Fernández-Arcos A, Tolosa E, <i> et al.</i>: Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. <i>PLoS One.</i> 2014; <b>9</b>(2): e89741. <a target=xrefwindow id=d48991e3977 href="http://www.ncbi.nlm.nih.gov/pubmed/24587002">PubMed Abstract </a> | <a target=xrefwindow id=d48991e3980 href="http://dx.doi.org/10.1371/journal.pone.0089741">Publisher Full Text </a> | <a target=xrefwindow id=d48991e3984 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3935943">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718294332">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726135948"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e3997 class=n-a></a>Migdalska-Richards A, Schapira AH: The relationship between glucocerebrosidase mutations and Parkinson disease. <i>J Neurochem.</i> 2016; <b>139</b>(Suppl 1): 77–90. <a target=xrefwindow id=d48991e4005 href="http://www.ncbi.nlm.nih.gov/pubmed/26860875">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4008 href="http://dx.doi.org/10.1111/jnc.13385">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5111601">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726135948">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725854032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4025 class=n-a></a>Berg D, Postuma RB, Adler CH, <i> et al.</i>: MDS research criteria for prodromal Parkinson's disease. <i>Mov Disord.</i> 2015; <b>30</b>(12): 1600–11. <a target=xrefwindow id=d48991e4036 href="http://www.ncbi.nlm.nih.gov/pubmed/26474317">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4039 href="http://dx.doi.org/10.1002/mds.26431">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725854032">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d48991e4052 class=n-a></a>Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, <i> et al.</i>: Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. <i>Mov Disord.</i> 2010; <b>25</b>(15): 2508–15. <a target=xrefwindow id=d48991e4063 href="http://www.ncbi.nlm.nih.gov/pubmed/20818670">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4066 href="http://dx.doi.org/10.1002/mds.23305">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d48991e4075 class=n-a></a>Hellenbrand W, Seidler A, Robra BP, <i> et al.</i>: Smoking and Parkinson's disease: a case-control study in Germany. <i>Int J Epidemiol.</i> 1997; <b>26</b>(2): 328–39. <a target=xrefwindow id=d48991e4086 href="http://www.ncbi.nlm.nih.gov/pubmed/9169168">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4089 href="http://dx.doi.org/10.1093/ije/26.2.328">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726721998"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4098 class=n-a></a>Spencer B, Williams S, Rockenstein E, <i> et al.</i>: <i>α</i>-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. <i>Ann Clin Transl Neurol.</i> 2016; <b>3</b>(8): 588–606. <a target=xrefwindow id=d48991e4112 href="http://www.ncbi.nlm.nih.gov/pubmed/27606342">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4116 href="http://dx.doi.org/10.1002/acn3.321">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4999592">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726721998">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718021753"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4132 class=n-a></a>Wagner J, Ryazanov S, Leonov A, <i> et al.</i>: Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. <i>Acta Neuropathol.</i> 2013; <b>125</b>(6): 795–813. <a target=xrefwindow id=d48991e4143 href="http://www.ncbi.nlm.nih.gov/pubmed/23604588">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4146 href="http://dx.doi.org/10.1007/s00401-013-1114-9">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3661926">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718021753">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725991503"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4163 class=n-a></a>Levin J, Schmidt F, Boehm C, <i> et al.</i>: The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. <i>Acta Neuropathol.</i> 2014; <b>127</b>(5): 779–80. <a target=xrefwindow id=d48991e4174 href="http://www.ncbi.nlm.nih.gov/pubmed/24615514">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4177 href="http://dx.doi.org/10.1007/s00401-014-1265-3">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4181 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3984662">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725991503">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725528588"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4195 class=n-a></a>Deeg AA, Reiner AM, Schmidt F, <i> et al.</i>: Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. <i>Biochim Biophys Acta.</i> 2015; <b>1850</b>(9): 1884–90. <a target=xrefwindow id=d48991e4206 href="http://www.ncbi.nlm.nih.gov/pubmed/26028294">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4209 href="http://dx.doi.org/10.1016/j.bbagen.2015.05.021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725528588">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d48991e4222 class=n-a></a>Koike MA, Price DL, White BM, <i> et al.</i>: The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology and biochemistry in the murine thy1-ASYN transgenic model of Parkinson’s disease. Society for Neuroscience Congress, Washington D.C. USA - poster 411.06/M1, 2014. <a target=xrefwindow id=d48991e4227 href="http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=0dba6d4a-507b-4e41-b065-40dc11fe8aab&amp;mID=3527&amp;mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7&amp;sKey=07411a22-9ccf-4b11-b7ee-5faebb10864a">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d48991e4236 class=n-a></a>Szoke B, Wrasidlo W, Stocking E, <i> et al.</i>: Biophysical characterization of the interaction of NPT200-11 with alpha-synuclein. Society for Neuroscience, Congress Washington D.C., USA - poster, 411.04/L11, 2014. <a target=xrefwindow id=d48991e4241 href="http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=46575e37-a6d9-40b6-b6e1-0efd39c7e5ec&amp;mID=3527&amp;mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7&amp;sKey=07411a22-9ccf-4b11-b7ee-5faebb10864a">Reference Source</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726786168"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4250 class=n-a></a>Wrasidlo W, Tsigelny IF, Price DL, <i> et al.</i>: A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's disease. <i>Brain.</i> 2016; <b>139</b>(pt 12): 3217–36. <a target=xrefwindow id=d48991e4264 href="http://www.ncbi.nlm.nih.gov/pubmed/27679481">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4268 href="http://dx.doi.org/10.1093/brain/aww238">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726786168">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d48991e4281 class=n-a></a>Höllerhage M, Moebius C, Melms J, <i> et al.</i>: High-throughput screening of FDA-approved drugs reveals PDE1 inhibition to protect against α-synuclein toxicity <i>in vitro</i> and in an <i>in vivo</i> mouse model of PD. <i>Acta Neuropathol.</i> (submitted).</span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726576364"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4302 class=n-a></a>Pagan F, Hebron M, Valadez EH, <i> et al.</i>: Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. <i>J Parkinsons Dis.</i> 2016; <b>6</b>(3): 503–17. <a target=xrefwindow id=d48991e4313 href="http://www.ncbi.nlm.nih.gov/pubmed/27434297">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4316 href="http://dx.doi.org/10.3233/JPD-160867">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4320 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5008228">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726576364">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d48991e4334 class=n-a></a>Hebron ML, Lonskaya I, Moussa CE: Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. <i>Hum Mol Genet.</i> 2013; <b>22</b>(16): 3315–28. <a target=xrefwindow id=d48991e4342 href="http://www.ncbi.nlm.nih.gov/pubmed/23666528">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4345 href="http://dx.doi.org/10.1093/hmg/ddt192">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4348 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3723316">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d48991e4357 class=n-a></a>Hebron ML, Lonskaya I, Olopade P, <i> et al.</i>: Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy. <i>J Clin Cell Immunol.</i> 2014; <b>5</b>: 259. <a target=xrefwindow id=d48991e4368 href="http://www.ncbi.nlm.nih.gov/pubmed/25635231">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4371 href="http://dx.doi.org/10.4172/2155-9899.1000259">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4375 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4308054">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312349"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4384 class=n-a></a>Donadio V, Incensi A, Leta V, <i> et al.</i>: Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease. <i>Neurology.</i> 2014; <b>82</b>(15): 1362–9. <a target=xrefwindow id=d48991e4395 href="http://www.ncbi.nlm.nih.gov/pubmed/24634456">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4398 href="http://dx.doi.org/10.1212/WNL.0000000000000316">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312349">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718372481"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4411 class=n-a></a>Doppler K, Ebert S, Uçeyler N, <i> et al.</i>: Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. <i>Acta Neuropathol.</i> 2014; <b>128</b>(1): 99–109. <a target=xrefwindow id=d48991e4422 href="http://www.ncbi.nlm.nih.gov/pubmed/24788821">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4425 href="http://dx.doi.org/10.1007/s00401-014-1284-0">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4429 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4059960">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718372481">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d48991e4442 class=n-a></a>Antelmi E, Donadio V, Incensi PG, <i> et al.</i>: Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder. <i>Neurology.</i> (In Press). </span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d48991e4457 class=n-a></a>Doppler K, Jentschke HM, Schulmeyer L, <i> et al.</i>: Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. <i>Acta Neuropathol.</i> 2017; 1–11. <a target=xrefwindow id=d48991e4465 href="http://www.ncbi.nlm.nih.gov/pubmed/28180961">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4468 href="http://dx.doi.org/10.1007/s00401-017-1684-z">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d48991e4478 class=n-a></a>Meles SK, Vadasz D, Renken RJ, <i> et al.</i>: Brain metabolic and dopaminergic imaging versus olfaction in rapid eye movement sleep behavior disorder. <i>Mov Disord.</i> (submitted). </span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d48991e4493 class=n-a></a>Zangaglia R, Stocchi F, Sciarretta M, <i> et al.</i>: Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. <i>Clin Neuropharmacol.</i> 2010; <b>33</b>(2): 61–6. <a target=xrefwindow id=d48991e4504 href="http://www.ncbi.nlm.nih.gov/pubmed/19935405">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4507 href="http://dx.doi.org/10.1097/WNF.0b013e3181c5e60c">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d48991e4516 class=n-a></a>Fasano A, Bove F, Gabrielli M, <i> et al.</i>: Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. <i>Clin Neuropharmacol.</i> 2014; <b>37</b>(4): 91–5. <a target=xrefwindow id=d48991e4527 href="http://www.ncbi.nlm.nih.gov/pubmed/24992085">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4530 href="http://dx.doi.org/10.1097/WNF.0000000000000034">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d48991e4539 class=n-a></a>Ferreira JJ, Rocha JF, Falcão A, <i> et al.</i>: Effect of opicapone on levodopa pharmacokinetics, catechol-<i>O</i>-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. <i>Eur J Neurol.</i> 2015; <b>22</b>(5): 815–25, e56. <a target=xrefwindow id=d48991e4553 href="http://www.ncbi.nlm.nih.gov/pubmed/25649051">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4557 href="http://dx.doi.org/10.1111/ene.12666">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d48991e4566 class=n-a></a>Michel A, Downey P, van Damme X, <i> et al.</i>: Behavioural Assessment of the A<sub>2a</sub>/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs. <i>PLoS One.</i> 2015; <b>10</b>(8): e0135949. <a target=xrefwindow id=d48991e4580 href="http://www.ncbi.nlm.nih.gov/pubmed/26322641">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4584 href="http://dx.doi.org/10.1371/journal.pone.0135949">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4587 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4555651">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d48991e4596 class=n-a></a>Hauser RA, Olanow CW, Kieburtz KD, <i> et al.</i>: Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurol.</i> 2014; <b>13</b>(8): 767–76. <a target=xrefwindow id=d48991e4607 href="http://www.ncbi.nlm.nih.gov/pubmed/25008546">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4610 href="http://dx.doi.org/10.1016/S1474-4422(14)70148-6">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d48991e4620 class=n-a></a>Perez-Lloret S, Merello M: Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. <i>Expert Opin Pharmacother.</i> 2014; <b>15</b>(8): 1097–107. <a target=xrefwindow id=d48991e4628 href="http://www.ncbi.nlm.nih.gov/pubmed/24673462">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4631 href="http://dx.doi.org/10.1517/14656566.2014.903924">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d48991e4640 class=n-a></a>Hacksell U, Burstein ES, McFarland K, <i> et al.</i>: On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. <i>Neurochem Res.</i> 2014; <b>39</b>(10): 2008–17. <a target=xrefwindow id=d48991e4651 href="http://www.ncbi.nlm.nih.gov/pubmed/24682754">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4654 href="http://dx.doi.org/10.1007/s11064-014-1293-3">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4172996">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5602956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4667 class=n-a></a>Chung KA, Lobb BM, Nutt JG, <i> et al.</i>: Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. <i>Neurology.</i> 2010; <b>75</b>(14): 1263–9. <a target=xrefwindow id=d48991e4678 href="http://www.ncbi.nlm.nih.gov/pubmed/20810998">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4681 href="http://dx.doi.org/10.1212/WNL.0b013e3181f6128c">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4685 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3013493">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5602956">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d48991e4698 class=n-a></a>Ravina B, Putt M, Siderowf A, <i> et al.</i>: Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. <i>J Neurol Neurosurg Psychiatr.</i> 2005; <b>76</b>(7): 934–9. <a target=xrefwindow id=d48991e4709 href="http://www.ncbi.nlm.nih.gov/pubmed/15965198">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4712 href="http://dx.doi.org/10.1136/jnnp.2004.050682">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4716 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1739697">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d48991e4725 class=n-a></a>Wills AM, Eberly S, Tennis M, <i> et al.</i>: Caffeine consumption and risk of dyskinesia in CALM-PD. <i>Mov Disord.</i> 2013; <b>28</b>(3): 380–3. <a target=xrefwindow id=d48991e4736 href="http://www.ncbi.nlm.nih.gov/pubmed/23339054">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4739 href="http://dx.doi.org/10.1002/mds.25319">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3608707">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d48991e4752 class=n-a></a>Postuma RB, Lang AE, Munhoz RP, <i> et al.</i>: Caffeine for treatment of Parkinson disease: a randomized controlled trial. <i>Neurology.</i> 2012; <b>79</b>(7): 651–8. <a target=xrefwindow id=d48991e4763 href="http://www.ncbi.nlm.nih.gov/pubmed/22855866">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4766 href="http://dx.doi.org/10.1212/WNL.0b013e318263570d">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3414662">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d48991e4780 class=n-a></a>Bhattacharyya S, Bakshi R, Logan R, <i> et al.</i>: Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. <i>Mov Disord.</i> 2016; <b>31</b>(3): 417–21. <a target=xrefwindow id=d48991e4791 href="http://www.ncbi.nlm.nih.gov/pubmed/26805433">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4794 href="http://dx.doi.org/10.1002/mds.26483">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1165821"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4803 class=n-a></a>Ascherio A, LeWitt PA, Xu K, <i> et al.</i>: Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Arch Neurol.</i> 2009; <b>66</b>(12): 1460–8. <a target=xrefwindow id=d48991e4814 href="http://www.ncbi.nlm.nih.gov/pubmed/19822770">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4817 href="http://dx.doi.org/10.1001/archneurol.2009.247">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2795011">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1165821">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d48991e4834 class=n-a></a>Simuni T, Biglan KM, Lowell J, <i> et al.</i>: An Update on STEADY-PD III. a phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort. International Movement Disorder Society Congress, Berlin, Germany – poster 2085. 2016. <a target=xrefwindow id=d48991e4839 href="http://www.mdsabstracts.org/abstract/steady-pd-iii-a-phase-3-study-of-isradipine-as-a-disease-modifying-agent-in-patients-with-early-parkinsons-disease-baseline-characteristics-of-the-enrolled-cohort/">Reference Source</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d48991e4848 class=n-a></a>Parkinson Study Group: Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). <i>Mov Disord.</i> 2013; <b>28</b>(13): 1823–31. <a target=xrefwindow id=d48991e4856 href="http://www.ncbi.nlm.nih.gov/pubmed/24123224">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4859 href="http://dx.doi.org/10.1002/mds.25639">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d48991e4868 class=n-a></a>Oertel WH, Brittinger C, Kamp C, <i> et al.</i>: The NIC-PD-study – baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and the USA. International Movement Disorder Congress, Berlin, Germany - abstract 1982, 2016. <a target=xrefwindow id=d48991e4873 href="http://www.mdsabstracts.org/abstract/the-nic-pd-study-baseline-data-of-a-randomized-placebo-controlled-double-blind-multi-centre-trial-to-assess-the-disease-modifying-potential-of-transdermal-nicotine-in-early-parkinsons-disea/">Reference Source</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d48991e4882 class=n-a></a>Quik M, O'Leary K, Tanner CM: Nicotine and Parkinson's disease: implications for therapy. <i>Mov Disord.</i> 2008; <b>23</b>(12): 1641–52. <a target=xrefwindow id=d48991e4890 href="http://www.ncbi.nlm.nih.gov/pubmed/18683238">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4893 href="http://dx.doi.org/10.1002/mds.21900">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4430096">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d48991e4906 class=n-a></a>Hong D, Fink AL, Uversky VN: Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? <i>Biochim Biophys Acta.</i> 2009; <b>1794</b>(2): 282–90. <a target=xrefwindow id=d48991e4914 href="http://www.ncbi.nlm.nih.gov/pubmed/19013262">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4917 href="http://dx.doi.org/10.1016/j.bbapap.2008.09.026">Publisher Full Text </a> | <a target=xrefwindow id=d48991e4920 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2647853">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d48991e4929 class=n-a></a>Schneeberger A, Tierney L, Mandler M: Active immunization therapies for Parkinson's disease and multiple system atrophy. <i>Mov Disord.</i> 2016; <b>31</b>(2): 214–24. <a target=xrefwindow id=d48991e4937 href="http://www.ncbi.nlm.nih.gov/pubmed/26260853">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4940 href="http://dx.doi.org/10.1002/mds.26377">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d48991e4949 class=n-a></a>Manoutcharian K, Perez-Garmendia R, Gevorkian G: Recombinant Antibody Fragments For Neurodegenerative Diseases. <i>Curr Neuropharmacol.</i> 2016. <a target=xrefwindow id=d48991e4954 href="http://www.ncbi.nlm.nih.gov/pubmed/27697033">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4957 href="http://dx.doi.org/10.2174/1570159X01666160930121647">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d48991e4966 class=n-a></a>Weihofen A, Patel H, Huy C, <i> et al.</i>: Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein <i>in vitro</i> and <i>in vivo</i>. International Movement Disorder Society Congress, Berlin, Germany - oral presentation, 2013. <a target=xrefwindow id=d48991e4977 href="http://www.mdsabstracts.org/abstract/human-derived-synuclein-antibody-biib054-binds-pathologic-forms-of-synuclein-and-attenuates-transmission-of-synuclein-in-vitro-and-in-vivo/">Reference Source</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726039947"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d48991e4986 class=n-a></a>Bergström AL, Kallunki P, Fog K: Development of Passive Immunotherapies for Synucleinopathies. <i>Mov Disord.</i> 2016; <b>31</b>(2): 203–13. <a target=xrefwindow id=d48991e4994 href="http://www.ncbi.nlm.nih.gov/pubmed/26704735">PubMed Abstract </a> | <a target=xrefwindow id=d48991e4997 href="http://dx.doi.org/10.1002/mds.26481">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726039947">F1000 Recommendation</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d48991e5010 class=n-a></a>Games D, Valera E, Spencer B, <i> et al.</i>: Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. <i>J Neurosci.</i> 2014; <b>34</b>(28): 9441–54. <a target=xrefwindow id=d48991e5021 href="http://www.ncbi.nlm.nih.gov/pubmed/25009275">PubMed Abstract </a> | <a target=xrefwindow id=d48991e5024 href="http://dx.doi.org/10.1523/JNEUROSCI.5314-13.2014">Publisher Full Text </a> | <a target=xrefwindow id=d48991e5028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4087215">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-260&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-260&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Neurology, University Clinic, Philipps Universit&auml;t Marburg, Marburg, Germany<br/> <sup>2</sup> Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-260/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 Mar 2017, 6:260 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10100.1">https://doi.org/10.12688/f1000research.10100.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Oertel WH. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10881 data-id=10100 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10100.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-260/v1/pdf?article_uuid=a8342594-31c1-4c9c-8d79-c7dfb96046c4" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10100.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Oertel WH. Recent advances in treating Parkinson’s disease [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):260 (<a href="https://doi.org/10.12688/f1000research.10100.1" target=_blank>https://doi.org/10.12688/f1000research.10100.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10100 id=mobile-track-article-signin-10100 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10100?target=/articles/6-260"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10881 /> <input name=articleId type=hidden value=10100 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Mark Hallett</strong>, Human Motor Control Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Peter LeWitt</strong>, School of Medicine, Wayne State University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-260&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-260&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=7988-20549></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=20852-20550></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-260/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 Mar 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Mark Hallett</strong>, Human Motor Control Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter LeWitt</strong>, School of Medicine, Wayne State University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-260&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-260/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in treating Parkinson\u2019s...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-260/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-260/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-260/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Oertel WH');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-260/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-260",
            templates : {
                twitter : "Recent advances in treating Parkinson\u2019s disease. Oertel WH, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-260/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in treating Parkinson\u2019s disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in treating Parkinson\u2019s disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10100/10881")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10881");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "20549": 0,
                           "20550": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "df15fc61-99ec-40f4-8b5b-066fb74c6bd0";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-260.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-260.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-260.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-260.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-260.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>